<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period - Middleton, P - 2021 | Cochrane Library</title> <meta content="Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period - Middleton, P - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001689.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period - Middleton, P - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001689.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001689.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period" name="citation_title"/> <meta content="Philippa Middleton" name="citation_author"/> <meta content="Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute" name="citation_author_institution"/> <meta content="Emily Shepherd" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="Judith C Gomersall" name="citation_author"/> <meta content="Women and Kids, South Australian Health and Medical Research Institute" name="citation_author_institution"/> <meta content="judith.gomersall@adelaide.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD001689.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001689.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001689.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001689.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [therapeutic use]; Bias; Cesarean Section; Heparin [therapeutic use]; Heparin, Low-Molecular-Weight [therapeutic use]; Pregnancy Complications, Hematologic [*prevention &amp; control]; Puerperal Disorders [*prevention &amp; control]; Randomized Controlled Trials as Topic; Venous Thrombosis [*prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001689.pub4&amp;doi=10.1002/14651858.CD001689.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001689\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001689\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001689.pub4",title:"Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period",firstPublishedDate:"Mar 29, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001689.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001689.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001689.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001689.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001689.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001689.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001689.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001689.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001689.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001689.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13574 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001689.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0194"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-sec-0188"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/appendices#CD001689-sec-0199"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/supinfo/CD001689StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/supinfo/CD001689StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information#CD001689-cr-0004">Philippa Middleton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information#CD001689-cr-0005">Emily Shepherd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information#CD001689-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Judith C Gomersall</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information/en#CD001689-sec-0209">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001689.pub4">https://doi.org/10.1002/14651858.CD001689.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001689-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001689-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001689-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001689-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001689-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001689-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001689-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD001689-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001689-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001689-abs-0001" lang="en"> <section id="CD001689-sec-0001"> <h3 class="title" id="CD001689-sec-0001">Background</h3> <p>Venous thromboembolism (VTE), although rare, is a major cause of maternal mortality and morbidity. Some women are at increased risk of VTE during pregnancy and the early postnatal period (e.g. caesarean section, family history of VTE, or thrombophilia), and so prophylaxis may be considered. As some methods of prophylaxis carry risks of adverse effects, and risk of VTE is often low, benefits of thromboprophylaxis may be outweighed by harms. </p> </section> <section id="CD001689-sec-0002"> <h3 class="title" id="CD001689-sec-0002">Objectives</h3> <p>To assess the effects of thromboprophylaxis during pregnancy and the early postnatal period on the risk of venous thromboembolic disease and adverse effects in women at increased risk of VTE. </p> </section> <section id="CD001689-sec-0003"> <h3 class="title" id="CD001689-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (18 October 2019). In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (18 October 2019). </p> </section> <section id="CD001689-sec-0004"> <h3 class="title" id="CD001689-sec-0004">Selection criteria</h3> <p>Randomised trials comparing one method of thromboprophylaxis with placebo or no treatment, or two (or more) methods of thromboprophylaxis. </p> </section> <section id="CD001689-sec-0005"> <h3 class="title" id="CD001689-sec-0005">Data collection and analysis</h3> <p>At least two review authors assessed trial eligibility, extracted data, assessed risk of bias, and judged certainty of evidence for selected critical outcomes (using GRADE). We conducted fixed‐effect meta‐analysis and reported data (all dichotomous) as summary risk ratios (RRs) with 95% confidence intervals (CIs). </p> </section> <section id="CD001689-sec-0006"> <h3 class="title" id="CD001689-sec-0006">Main results</h3> <p>Twenty‐nine trials (involving 3839 women), overall at moderate to high risk of bias were included. Trials were conducted across the antenatal, peripartum and postnatal periods, with most in high‐income countries. Interventions included types and regimens of heparin (low molecular weight heparin (LMWH) and unfractionated heparin (UFH)), hydroxyethyl starch (HES), and compression stockings or devices. Data were limited due to a small number of trials in comparisons and/or few or no events reported. All critical outcomes (assessed for comparisons of heparin versus no treatment/placebo, and LMWH versus UFH) were considered to have very low‐certainty evidence, downgraded mainly for study limitations and imprecise effect estimates.  Maternal death was not reported in most studies. </p> <p><b>Antenatal (± postnatal) prophylaxis</b> </p> <p>For the primary outcomes symptomatic thromboembolic events pulmonary embolism (PE) and/or deep vein thrombosis (DVT), and the critical outcome of adverse effects sufficient to stop treatment, the evidence was very uncertain.  </p> <p>Symptomatic thromboembolic events:</p> <p>‐ heparin versus no treatment/placebo (RR 0.39; 95% CI 0.08 to 1.98; 4 trials, 476 women; very low‐certainty evidence); </p> <p>‐ LMWH versus UFH (RR 0.47; 95% CI 0.09 to 2.49; 4 trials, 404 women; very low‐certainty evidence); </p> <p>Symptomatic PE:</p> <p>‐ heparin versus no treatment/placebo (RR 0.33; 95% CI 0.02 to 7.14; 3 trials, 187 women; very low‐certainty evidence); </p> <p>‐ LMWH versus UFH (no events; 3 trials, 287 women);</p> <p>Symptomatic DVT:</p> <p>‐ heparin versus no treatment/placebo (RR 0.33; 95% CI 0.04 to 3.10; 4 trials, 227 women; very low‐certainty evidence); </p> <p>‐ LMWH versus UFH (no events; 3 trials, 287 women);</p> <p>Adverse effects sufficient to stop treatment:</p> <p>‐ heparin versus no treatment/placebo (RR 0.49; 95% CI 0.05 to 5.31; 1 trial, 139 women; very low‐certainty evidence); </p> <p>‐ LMWH versus UFH (RR 0.07; 95% CI 0.01 to 0.54; 2 trials, 226 women; very low‐certainty evidence). </p> <p><b>Peripartum/postnatal prophylaxis</b> </p> <p><i><b>Vaginal or caesarean birth</b> </i> </p> <p>When UFH and no treatment were compared, the effects on symptomatic thromboembolic events (RR 0.16; 95% CI 0.02 to 1.36; 1 trial, 210 women; very low‐certainty evidence), symptomatic PE (RR 0.16; 95% CI 0.01 to 3.34; 1 trial, 210 women; very low‐certainty evidence), and symptomatic DVT  (RR 0.27; 95% CI 0.03 to 2.55; 1 trial, 210 women; very low‐certainty evidence) were very uncertain.  Maternal death and adverse effects sufficient to stop treatment were not reported. </p> <p><i><b>Caesarean birth</b> </i> </p> <p>Symptomatic thromboembolic events:</p> <p>‐ heparin versus no treatment/placebo (RR 1.30; 95% CI 0.39 to 4.27; 4 trials, 840 women; very low‐certainty evidence); </p> <p>‐ LMWH versus UFH (RR 0.33; 95% CI 0.01 to 7.99; 3 trials, 217 women; very low‐certainty evidence); </p> <p>Symptomatic PE:</p> <p>‐ heparin versus no treatment/placebo (RR 1.10; 95% CI 0.25 to 4.87; 4 trials, 840 women; very low‐certainty evidence); </p> <p>‐ LMWH versus UFH (no events; 3 trials, 217 women); </p> <p>Symptomatic DVT:</p> <p>‐ heparin versus no treatment/placebo (RR 1.30; 95% CI 0.24 to 6.94; 5 trials, 1140 women; very low‐certainty evidence); LMWH versus UFH (RR 0.33; 95% CI 0.01 to 7.99; 3 trials, 217 women; very low‐certainty evidence); </p> <p>Maternal death:</p> <p>‐ heparin versus placebo (no events, 1 trial, 300 women);</p> <p>Adverse effects sufficient to stop treatment:</p> <p>‐ heparin versus placebo (no events;  1 trial, 140 women).</p> <p><b>Postnatal prophylaxis</b> </p> <p>No events were reported for LMWH versus no treatment/placebo for: symptomatic thromboembolic events, symptomatic PE and symptomatic DVT (all 2 trials, 58 women), or maternal death (1 trial, 24 women). Adverse effects sufficient to stop treatment were not reported. </p> <p>We were unable to conduct subgroup analyses due to lack of data.</p> <p>Sensitivity analysis including the nine studies at low risk of bias did not impact overall findings. </p> </section> <section id="CD001689-sec-0007"> <h3 class="title" id="CD001689-sec-0007">Authors' conclusions</h3> <p>The evidence is very uncertain about benefits and harms of VTE thromboprophylaxis in women during pregnancy and the early postnatal period at increased risk of VTE. Further high‐quality very large‐scale randomised trials are needed to determine effects of currently used treatments in women with different VTE risk factors. As sufficiently large definitive trials are unlikely to be funded, secondary data analyses based on high‐quality registry data are important. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001689-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001689-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001689-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001689-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001689-abs-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001689-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001689-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001689-abs-0019">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001689-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001689-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001689-abs-0022">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001689-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001689-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001689-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001689-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001689-abs-0002" lang="en"> <h3>Preventing venous thromboembolism in women during pregnancy, childbirth and after birth </h3> <p>We set out to determine from randomised controlled trials the benefits and harms of treatments during pregnancy, childbirth, and after birth to prevent deep vein clots in women who are at increased risk. </p> <p><b>What is the issue?</b> </p> <p>A blood clot can form in a deep vein, usually in the legs. This is known as deep vein thrombosis (DVT). If part of the clot breaks off it can be carried in the blood to the lungs and block blood vessels there. This is called a pulmonary embolism (PE), and can cause death, although this is rare. Together these are known as venous thromboembolism (VTE) disease. A women's clotting system is more active during pregnancy to protect her from excessive bleeding during birth. Some women are at a higher risk of VTE during pregnancy and around the time of childbirth including women with previous VTE, thrombophilia (a condition which makes people more likely to develop clots) and following a caesarean birth. </p> <p><b>Why is this important?</b> </p> <p>Women at increased risk of VTE during pregnancy and in the six weeks following childbirth are commonly given treatments to prevent blood clots. Treatments vary due to lack of clear guidelines. The treatments to prevent VTE include heparin type drugs, aspirin and the wearing of compression stockings to improve blood flow in the legs. Some of the treatments can potentially harm women, for example, by increasing blood loss after childbirth or interfering with wound healing. </p> <p><b>What evidence did we find?</b> </p> <p>This is an update of a Cochrane Review published in 2014. We searched for new evidence in October 2019. Twenty‐nine randomised controlled studies, involving 3839 women, are now included. The studies were published from 1975 to 2016 and were mainly carried out in high‐income countries. They included women at increased risk of VTE who were pregnant, in childbirth, and after the birth. Treatments assessed included different types and doses of heparin (of low molecular weight heparin and unfractionated heparin), and compression stockings or devices. No deaths occurred. The reported findings were supported by very low‐certainty evidence. </p> <p>Starting treatment during pregnancy (with or without treatment after childbirth): we looked at the occurrence of symptomatic VTE and adverse effects that caused women to stop treatment. Any benefits of heparin were unclear when compared with no treatment or a placebo (assessed in up to four studies with 476 women). Similarly, for different types of heparin (assessed in up to four studies with 404 women), different doses of low molecular weight heparin (in one study with 144 women), and for compression stockings compared with no stockings (in one study with 44 women). </p> <p>For treatment during and following vaginal or caesarean birth: we are very uncertain about the effects of heparin when compared with no treatment on the occurrence of symptomatic VTE (assessed in one study with 210 women). This study did not report on adverse effects that led women to stop treatment. </p> <p>For treatment during and following caesarean birth: we are very uncertain about the effects of heparin compared with no treatment or a placebo (assessed in up to five studies with 1140 women). The studies looked at different types or doses of heparin, and compression devices compared with bed rest (in one study of 49 women). No adverse effects stopping treatment were reported. </p> <p>Looking at treatment following vaginal or caesarean birth: no symptomatic VTEs were reported in women receiving either heparin or no treatment or placebo in two studies (58 women). No study reported on adverse effects leading to women stopping treatment. </p> <p><b>What does this mean?</b> </p> <p>We are very uncertain if the benefits of treatments used to prevent deep vein clots in high‐risk women during pregnancy and around the time of childbirth outweigh any harms. Small numbers of studies were included in the comparisons with a range of outcomes measured and low numbers of events. Some studies had design limitations and definitions of blood clotting risk factors and outcomes were not always clear. More, large, high‐quality studies are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001689-sec-0194" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001689-sec-0194"></div> <h3 class="title" id="CD001689-sec-0195">Implications for practice</h3> <section id="CD001689-sec-0195"> <p>Current evidence is very uncertain regarding the effects of thromboprophylaxis during pregnancy and the early postnatal period on the risk of venous thromboembolic disease and adverse effects in women at increased risk of venous thromboembolism (VTE). </p> <p>Effects were very uncertain (or not estimable due to no events) across all antenatal, intrapartum and postnatal comparisons that reported critical outcomes: symptomatic thromboembolic events, symptomatic pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT) and/or adverse effects sufficient to stop treatment. Evidence for these critical outcomes was assessed as very low‐certainty due mainly to trial design limitations and considerable imprecision (usually due to low event rates and small numbers of trials and participants per outcome). No maternal deaths were reported. </p> </section> <h3 class="title" id="CD001689-sec-0196">Implications for research</h3> <section id="CD001689-sec-0196"> <p>There is a need for certain evidence from rigorously conducted large‐scale randomised controlled trials assessing the effects of methods of thromboprophylaxis on rare outcomes such as thromboembolic events. However, the low number of eligible women, and the need to include very large numbers of women in each trial arm to show a difference in incidence of rare outcomes makes conducting trials of antenatal thromboprophylaxis extremely challenging. To achieve an adequate sample size, a trial needs to be conducted in a very large number of centres, in a range of countries, and involve much international collaboration. Acquiring funding for such trials is difficult, and highly unlikely. Rigorous observational studies based on registry data, for example the Riete Registry, the worlds largest database on patients with VTE, are more feasible, and are therefore warranted to address the gaps in evidence about the safety and effectiveness of VTE prophylaxis for high‐risk women during pregnancy and the early postnatal period. </p> <p>Future studies need to address currently used treatments. Standardised reporting of a comprehensive range of critical outcomes would facilitate combining effect estimates from individual trials in meta‐analyses. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001689-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001689-sec-0008"></div> <div class="table" id="CD001689-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment/placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment/placebo for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> pregnant women at increased risk of VTE during pregnancy and the early postnatal period </p> <p><b>Settings:</b> UK (2 trials), Australia and Sweden (1 trial), Canada and USA (1 trial), Australia, the Netherlands and Sweden (1 trial) </p> <p><b>Intervention:</b> heparin (LMWH (4 trials) or UFH (1 trial)) </p> <p><b>Comparison:</b> no treatment (3 trials) or placebo (2 trials) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no treatment/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(follow‐up: 6 weeks postpartum</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.39 (0.08 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>476</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 trial reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000 (1 to 34)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33 (0.02 to 7.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 trials reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 77) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33 (0.04 to 3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 trials reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 (1 to 55)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.49 (0.05 to 5.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>139</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 3, 4</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 events: heparin (LMWH) 1 event (bleeding from placental praevia); no treatment 2 events (both stomach complaints) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(1 to 154) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>LMWH</b> : low molecular weight heparin; <b>PE:</b> pulmonary embolism; <b>RR:</b> Risk Ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of selective reporting bias; not downgraded for lack of blinding as unlikely to have influenced objective outcome </p> <p><sup>2</sup> Imprecision (‐2): few events and wide confidence intervals crossing the line of no effect </p> <p><sup>3</sup> Indirectness (‐1): women had specific risk factors for VTE during pregnancy and the postpartum period which varied across the trials, and risk factors also varied across women within the trials, limiting applicability of results to all pregnant women and women in the early postnatal period at increased risk of VTE </p> <p><sup>4</sup> Imprecision (‐2): few events and small sample size </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001689-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: LMWH versus UFH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antenatal (± postnatal)</b> <b>prophylaxis: LMWH versus UFH for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> pregnant women at increased risk of VTE during pregnancy and the early postnatal period </p> <p><b>Settings:</b> Finland (1 trial), USA (3 trials) </p> <p><b>Intervention:</b> LMWH </p> <p><b>Comparison:</b> UFH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(Follow‐up: during or immediately following delivery or 6‐8 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.47 (0.09 to 2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>404</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 trials reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(2 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(Follow‐up: during or immediately following delivery or 6‐8 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>287<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><sup>⊕⊝⊝⊝</sup> </p> <p>very low <sup>1, 4, 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(Follow‐up: during or immediately following delivery or 6‐8 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>287</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><sup>⊕⊝⊝⊝</sup> </p> <p>very low <sup>1, 4, 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.07 (0.01 to 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>226</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1,</sup><sup>6, 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13 events in UFH group: 1 stopped due to an allergic reaction, 1 due to mild anaemia with no confirmed bleeding and 11 due to excess bruising/allergic rashes (these 11 stopped switched to LMWH (dalteparin) and the adverse effects resolved) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(1 to 61) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT</b> : deep vein thrombosis; <b>LMWH</b> : low molecular weight heparin; <b>NA</b> : not applicable; <b>PE:</b> pulmonary embolism; <b>RR:</b> Risk Ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of selection, attrition and selective reporting bias; not downgraded for lack of blinding as inadequate blinding unlikely to have influenced objective outcome </p> <p><sup>2</sup> Imprecision (‐2): few events and wide confidence interval crossing line of no effect </p> <p><sup>3</sup> Indirectness (‐1): not clear if the events were symptomatic, described as "recurrent thrombosis"; further women had specific risk factors, limiting applicability of results to all pregnant women and women in the early postnatal period at increased risk of VTE </p> <p><sup>4</sup> Imprecision (‐2): no events and small sample size </p> <p><sup>5</sup> Indirectness (‐1): women had specific risk factors, limiting applicability of results to all pregnant women and women in the early postnatal period at increased risk of VTE </p> <p><sup>6</sup> Few events and small sample size </p> <p><sup>7</sup> Indirectness (‐1): risk factors for VTE poorly described in 1 of the trials (with most weight in the meta‐analysis) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001689-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Peripartum/postnatal prophylaxis: UFH versus no treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peripartum/postnatal prophylaxis: UFH versus no treatment for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth </p> <p><b>Settings:</b> Israel (1 RCT) </p> <p><b>Intervention:</b> UFH </p> <p><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no UFH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16 (0.02 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(1 to 72)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16 (0.01 to 3.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 71)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27 (0.03 to 2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(1 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk Ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of all sources of bias other than attrition (low risk); not downgraded for lack of blinding as objective outcome </p> <p><sup>2</sup> Imprecision (‐2): wide confidence intervals crossing line of no effect, few events, and small sample size </p> <p><sup>3</sup> Indirectness (‐1): specific risk factors for VTE of included women limits applicability of findings to all women at increased risk of VTE intrapartum and in the early postnatal period </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001689-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment/placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment/placebo for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials)) </p> <p><b>Settings:</b> Australia (1 trial), Saudi Arabia (1 trial), Switzerland (1 trial), UK (2 trials) </p> <p><b>Intervention:</b> heparin <b>(</b>LMWH (3 RCTs), UFH (2 RCTs)) </p> <p><b>Comparison</b>: no treatment (1 trial) or placebo (4 trials) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no heparin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal death</p> <p>(timing of assessment unclear)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA<br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> 300</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> ⊕⊝⊝⊝</p> <p>very low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events<br/> <br/> <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30 (0.39 to 4.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>840</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(4 to 29)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10 (0.25, 4.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>840<br/>(4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(2 to 33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.30 (0.24, 6.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1140<br/>(5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(1 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>2, 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>NA</b> : not applicable; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk Ratio; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐2) one trial at unclear risk of all sources of bias </p> <p><sup>2</sup> Imprecision (‐2): no events and small sample size </p> <p><sup>3</sup> Design limitations (‐2): most trials at unclear risk of selection bias, all trials at unclear risk of selective reporting; not downgraded for lack of blinding as objective outcome </p> <p><sup>4</sup> Imprecision (‐1): wide confidence intervals crossing line of no effect </p> <p><sup>5</sup> Design limitations (‐1): unclear risk of selective reporting bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001689-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial), elective/emergency unclear (1 trial)) </p> <p><b>Settings:</b> German (2 trials); UK (1 trial) </p> <p><b>Intervention:</b> LMWH </p> <p><b>Comparison:</b> UFH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33 (0.01 to 7.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>217<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All the events were symptomatic DVT</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>2 to 75) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>217<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>1, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Symptomatic DVT</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33 (0.01 to 7.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>217<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000<br/>2 to 75) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>LMWH</b> : low molecular weight heparin; <b>NA</b> : not applicable; PE: pulmonary embolism; <b>RR:</b> Risk Ratio; <b>UFH</b>: unfractionated heparin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐2): all trials at unclear risk of selection bias, selective reporting and other bias; not downgraded for lack of blinding as objective outcome </p> <p><sup>2</sup> Imprecision (‐2): wide confidence intervals crossing line of no effect, few events and small sample size </p> <p><sup>3</sup> Imprecision (‐2): no events and small sample size </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001689-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Postnatal prophylaxis: LMWH versus no treatment/placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Postnatal prophylaxis: LMWH versus no treatment/placebo</b> <b>for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women at increased risk of VTE in the early postpartum period </p> <p><b>Settings:</b> multi‐country, Canada and USA (2 trials) </p> <p><b>Intervention:</b> LMWH </p> <p><b>Comparison:</b> no treatment (1 trial) or placebo (1 trial) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with no heparin treatment or placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> <p>Maternal death only reported as: “no… other unexpected serious adverse events related to the intervention during follow‐up” </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(follow‐up: 10‐90 days postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58<br/>(2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(follow‐up: 10‐90 days postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58<br/>(2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(follow‐up: 10‐90 days postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>NA</b> : not applicable; <b>PE:</b> pulmonary embolism; <b>RR:</b> Risk Ratio; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of selective reporting and other bias </p> <p><sup>2</sup> Imprecision (‐2): no events and small sample size </p> <p><sup>3</sup> Design limitations (‐1): unclear risk of selective reporting and other bias; not downgraded for lack of blinding as objective outcome </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001689-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001689-sec-0009"></div> <section id="CD001689-sec-0010"> <h3 class="title" id="CD001689-sec-0010">Description of the condition</h3> <section id="CD001689-sec-0011"> <h4 class="title">Venous thromboembolic disease in pregnancy and the early postnatal period</h4> <p>Venous thromboembolism (VTE) is a condition where the blood clots inappropriately, and which may lead to considerable morbidity and even death. The term VTE encompasses a continuum, including both deep vein thrombosis (DVT) (the formation of clots in the deep veins of the body ‐ predominately in the legs), and pulmonary embolism (PE) (which occurs when a clot in a deep vein breaks free and is carried to the arteries of the lungs) (<a href="./references#CD001689-bbs2-0088" title="Di NisioM , vanEsN , BüllerHR . Deep vein thrombosis and pulmonary embolism. Lancet2017;388(10063):3060-73.">Di Nisio 2017</a>; <a href="./references#CD001689-bbs2-0092" title="GoldhaberSZ , BounameauxH . Pulmonary embolism and deep vein thrombosis. Lancet2012;379:1835-46.">Goldhaber 2012</a>). Two of the most common initial symptoms of DVT are pain and swelling in an extremity (such as the lower leg), while symptoms and signs of PE include dyspnoea (shortness of breath), tachypnoea (rapid breathing), chest pain and haemoptysis (coughing up blood). Severe cases of PE can include signs of cyanosis (blue discolouration, particularly of the lips and fingers), and may result in collapse and sudden death (<a href="./references#CD001689-bbs2-0078" title="American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. Obstetrics and Gynecology2018;132:e1-17.">ACOG 2018</a><a href="./references#CD001689-bbs2-0088" title="Di NisioM , vanEsN , BüllerHR . Deep vein thrombosis and pulmonary embolism. Lancet2017;388(10063):3060-73.">Di Nisio 2017</a>; <a href="./references#CD001689-bbs2-0077" title="AbbasiN , BalaylaJ , LaportaDP , KezouhA , AbenhaimHA . Trends, risk factors and mortality among women with venous thromboembolism during labour and delivery: a population based study of 8 million births. Archives of Gynecology and Obstetrics2014;289(2):275-84.">Abbasi  2014</a> ; <a href="./references#CD001689-bbs2-0093" title="GreerIA . Thrombosis in pregnancy: updates in diagnosis and management. Hematologic Diseases in Pregnancy2012;2012:203-5.">Greer 2012</a>; <a href="./references#CD001689-bbs2-0099" title="KnightM . Antenatal pulmonary emboism: risk factors, management and outcomes. BJOG: an international journal of obstetrics and gynaecology2008;115:453-61.">Knight 2008</a> ; <a href="./references#CD001689-bbs2-0097" title="JacobsenA , SkjeldestadFE , Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium - a register-based case-control study. American Journal of Obstetrics andGynecology2008;198(233):e1-7.">Jacobsen 2008</a>; <a href="./references#CD001689-bbs2-0098" title="JamesAH , JamisonMG , BrancazioLR . Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. American Journal of Obstetrics and Gynecology2006;194:1311–5.">James 2006</a>). Approximately 75% to 80% of cases of pregnancy‐associated VTE are caused by DVT, and 20% to 25% of cases are caused by PE  (<a href="./references#CD001689-bbs2-0084" title="Blanco-MolinaA , RotaL , Di MiccoP , BrennerB , Tujilo-SantosJ , Ruiz-GamieteaA , et al. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. RIETE Investigators. Thombosis and Haemostasis2010;103:306-11.">Blanco‐Molina 2010</a>; <a href="./references#CD001689-bbs2-0098" title="JamesAH , JamisonMG , BrancazioLR . Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. American Journal of Obstetrics and Gynecology2006;194:1311–5.">James 2006</a>; <a href="./references#CD001689-bbs2-0114" title="SimpsonEL , LawrensonRA , NightingaleAL , FarmerRD . Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. British Journal of Obstetrics and Gynaecology2001;108(1):56-60.">Simpson 2001</a>). </p> <p>Pregnancy is associated with a number of physiological and anatomic changes that can increase the risk of VTE (<a href="./references#CD001689-bbs2-0078" title="American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. Obstetrics and Gynecology2018;132:e1-17.">ACOG 2018</a>; <a href="./references#CD001689-bbs2-0081" title="AntonyKM , RacusinDA , AagaardK , DildyGA . III Maternal physiology. In: GabbeSG , NiebylJR , SimpsonJO , LandonMB , GalanHL , Jauniaux ER et al, editors(s). Obstetrics: Normal and Problem Pregnancies. 7th edition. Philadelphia: Elsevier, 2017.">Antony 2017</a>). </p> </section> </section> <section id="CD001689-sec-0012"> <h3 class="title" id="CD001689-sec-0012">Description of the intervention</h3> <section id="CD001689-sec-0013"> <h4 class="title">Thromboprophylaxis</h4> <p>The intervention assessed in this review covers VTE thromboprophylaxis (measures taken in order to prevent thrombosis), including pharmacological agents and non pharmacological methods. Despite evidence correlating risk factors and the occurrence of pregnancy‐related VTE being imprecise (<a href="./references#CD001689-bbs2-0078" title="American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. Obstetrics and Gynecology2018;132:e1-17.">ACOG 2018</a>; <a href="./references#CD001689-bbs2-0105" title="OkorohEN , AzonobiIC , GrosseSD , GrantAM , AtrashHK , JamesAH . Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000–2011. Journal of Women's Health2012;21(6):611-5.">Okoroh 2012</a>), there is broad agreement that women should be assessed for VTE risk preconception, and again during pregnancy, in order to guide VTE thromboprophylaxis (<a href="./references#CD001689-bbs2-0091" title="FriedmanA , AnanthC . Obstetrical venous thromboembolism: Epidemiology and strategies for prophylaxis. Seminars in Perinatology2016;40:81-6.">Friedman 2016</a>; <a href="./references#CD001689-bbs2-0103" title="National Health and Medical Research Council. Clinical Practice Guideline for the Prevention of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Australian Hospitals. Melbourne: National Health and Medical Research Council, 2009.">NHMRC 2009</a>). </p> <p>Globally, guidelines (for example of the American College of Obstetricians and Gynecologists (ACOG) (<a href="./references#CD001689-bbs2-0078" title="American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. Obstetrics and Gynecology2018;132:e1-17.">ACOG 2018</a>), the American College of Chest Physicians (ACCP) (<a href="./references#CD001689-bbs2-0082" title="BatesSM , GreerIA , MiddeldorpS , VeenstraDL , PrabulosAM , VandvikPO . VTE, thrombophilia, antithrombotic therapy,and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(2 Suppl):e691S–e6736.">Bates 2012</a>), National Institute for Health and Care Excellence (<a href="./references#CD001689-bbs2-0104" title="NICE 2018. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89). www.nice.org.uk/guidance/ng892018.">NICE 2018</a>) and the Royal College of Obstetricians and Gynaecologists (RCOG) (<a href="./references#CD001689-bbs2-0110" title="The Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and puerperium. Green-top guideline. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/2015:1-40.">RCOG 2015</a>)), are unanimous in their recommendations that all women undergo a documented assessment of risk factors for VTE in early pregnancy or prepregnancy, and women judged to be at high risk of VTE be offered thromboprophylaxis, where benefit is likely to outweigh potential harms. However, the available guidelines do not reach consensus regarding groups of women at higher risk of VTE, and which type of thromboprophylaxis should be offered. They also differ in the treatment options advised for particular groups of women at increased risk of VTE, including timing of interventions (starting points and lengths of treatments). Pregnancy‐specific guidelines for thromboprophylaxis in COVID‐19 have been published, though are lacking high‐certainty evidence to inform clinical practice (<a href="./references#CD001689-bbs2-0086" title="D'SouzaR , MalhaméI , TeshlerL , AcharyaG , HuntBJ , McLintockC . A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19. Acta Obstetricia et Gynecologica Scandinavica2020;Jul 17 [Epub ahead of print]. [DOI: 10.1111/aogs.13962]">D'Souza 2020</a>). </p> <p>ACCP and ACOG guidelines advise antenatal and postpartum pharmacologic prophylaxis for a small group of particularly high‐risk women ‐ those women with prior events, and/or thrombophilias. For women undergoing caesarean birth, ACOG supports universal perioperative mechanical prophylaxis and ACCP recommends pharmacologic prophylaxis based on risk factors. In comparison, RCOG recommends pharmacologic prophylaxis to a much larger proportion of women based on common risk factors (<a href="./references#CD001689-bbs2-0078" title="American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. Obstetrics and Gynecology2018;132:e1-17.">ACOG 2018</a> ; <a href="./references#CD001689-bbs2-0091" title="FriedmanA , AnanthC . Obstetrical venous thromboembolism: Epidemiology and strategies for prophylaxis. Seminars in Perinatology2016;40:81-6.">Friedman 2016</a>). </p> <p>Pharmacological agents that have been used to prevent thrombosis around pregnancy include: </p> <p> <ul id="CD001689-list-0001"> <li> <p>unfractionated heparin (UFH) or low molecular weight heparin (LMWH);</p> </li> <li> <p>aspirin, a platelet aggregation inhibitor;</p> </li> <li> <p>hydroxyethyl starch (HES), a nonionic starch derivative;</p> </li> <li> <p>fondaparinux, a selective inhibitor of activated Factor X;</p> </li> <li> <p>danaparoid, a heparinoid.</p> </li> </ul> </p> <p>Non‐pharmacological methods used include:</p> <p> <ul id="CD001689-list-0002"> <li> <p>graduated compression stockings;</p> </li> <li> <p>intermittent pneumatic compression;</p> </li> <li> <p>early mobilisation;</p> </li> <li> <p>surveillance.</p> </li> </ul> </p> </section> </section> <section id="CD001689-sec-0014"> <h3 class="title" id="CD001689-sec-0014">How the intervention might work</h3> <section id="CD001689-sec-0015"> <h4 class="title">Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period </h4> <p>Thrombin has a key role in haemostasis and thrombosis, and thus anticoagulant strategies focus on either inhibiting thrombin or its generation. UFH, LMWH and coumarin derivatives (such as warfarin) prevent the generation of thrombin through a variety of mechanisms (<a href="./references#CD001689-bbs2-0080" title="AnsellJ , BergqvistD . Current options in the prevention of thromboembolic disease. Drugs2004;64(Suppl 1):1-5.">Ansell 2004</a>). Heparins (such as UFH and LMWH) exert their anticoagulant activity by activating antithrombin, which subsequently inhibits thrombin (and Factor Xa). Coumarin derivatives (such as warfarin) however, produce their anticoagulant effect by interfering with the cyclic conversion of vitamin K (which is required as a co‐factor for the 'carboxylation' of vitamin K‐dependent proteins, which include a number of coagulation factors); by blocking this process, the coagulation factors that are produced have no/little biological activity. Selective inhibitors of activated Factor Xa (such as fondaparinux), exert their antithrombotic activity by neutralisation of Factor Xa, which interrupts the blood coagulation cascade, inhibiting thrombin formation and thrombus development (<a href="./references#CD001689-bbs2-0080" title="AnsellJ , BergqvistD . Current options in the prevention of thromboembolic disease. Drugs2004;64(Suppl 1):1-5.">Ansell 2004</a>). </p> <p>Non‐pharmacological methods, such as graduated compression stockings or intermittent pneumatic compression may work through their ability to reduce venous stasis and blood stagnation by promoting venous blood flow through external compression (<a href="./references#CD001689-bbs2-0103" title="National Health and Medical Research Council. Clinical Practice Guideline for the Prevention of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Australian Hospitals. Melbourne: National Health and Medical Research Council, 2009.">NHMRC 2009</a>). </p> <p>Despite previously established benefits of thromboprophylaxis for VTE in non‐pregnant patient groups, evidence on the effects, and cost‐effectiveness of thromboprophylaxis is scant and unclear (<a href="./references#CD001689-bbs2-0090" title="Ellis-KahanaJ , SparksA , GimovskyA , JamesA , AhmadziaH . Developing a model for predicting venous thromboembolism in obese pregnant women in a national study. Thrombosis Research2020;191:42-9.">Ellis‐Kahana 2020</a>; <a href="./references#CD001689-bbs2-0091" title="FriedmanA , AnanthC . Obstetrical venous thromboembolism: Epidemiology and strategies for prophylaxis. Seminars in Perinatology2016;40:81-6.">Friedman 2016</a>; <a href="./references#CD001689-bbs2-0107" title="PalmerolaKL , D' AltonME , BrockCO , FriedmanAM . A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines. BJOG: an international journal of obstetrics and gynaecology2016;123(13):2157-62.">Palmerola 2015</a>). There is ongoing debate about whether potential benefits outweigh potential harms in some groups of high‐risk women (<a href="./references#CD001689-bbs2-0078" title="American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. Obstetrics and Gynecology2018;132:e1-17.">ACOG 2018</a>), and whether they should be routinely screened for treatment. Routine screening of all pregnant women to identify women with thrombophilia, for example, has not been recommended (<a href="./references#CD001689-bbs2-0105" title="OkorohEN , AzonobiIC , GrosseSD , GrantAM , AtrashHK , JamesAH . Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000–2011. Journal of Women's Health2012;21(6):611-5.">Okoroh 2012</a>), and antenatal prophylaxis for all women with known thrombophilia remains controversial (<a href="./references#CD001689-bbs2-0085" title="BrennerB . Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications--Yes. Journal of Thrombosis and Haemostasis2003;1(10):2070-2.">Brenner 2003</a>; <a href="./references#CD001689-bbs2-0087" title="deJongPG , KaandorpS , Di NisioM , GoddijnM , MiddeldorpS . Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD004734. [DOI: 10.1002/14651858.CD004734]">de Jong 2014</a>; <a href="./references#CD001689-bbs2-0091" title="FriedmanA , AnanthC . Obstetrical venous thromboembolism: Epidemiology and strategies for prophylaxis. Seminars in Perinatology2016;40:81-6.">Friedman 2016</a>; <a href="./references#CD001689-bbs2-0101" title="MiddeldorpS . Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications--No. Journal of Thrombosis and Haemostasis2003;1(10):2073-4.">Middeldorp 2003</a>; <a href="./references#CD001689-bbs2-0105" title="OkorohEN , AzonobiIC , GrosseSD , GrantAM , AtrashHK , JamesAH . Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000–2011. Journal of Women's Health2012;21(6):611-5.">Okoroh 2012</a>; <a href="./references#CD001689-bbs2-0116" title="WuO , RobertsonL , TwaddleS , LoweG , ClarkP , WalkerI , et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. British Journal of Haematology2005;131(1):80-90.">Wu 2005</a>). </p> <p>Pharmacological prophylaxis may cause adverse effects that could be sufficiently severe to outweigh the benefits of thromboprophylaxis. Heparin does not cross the placenta and is believed to be safe for the fetus, and therefore, has generally been used for antenatal therapy. However, it can result in adverse effects for the mother (<a href="./references#CD001689-bbs2-0102" title="Nelson-PiercyC . Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Bailliere's Clinical Obstetrics and Gynaecology1997;11:489-509.">Nelson‐Piercy 1997</a>); there is a risk of thrombocytopenia (low numbers of platelets), bleeding and allergic reactions and symptomatic osteoporosis (loss of bone density, leading to fractures) in the longer term. When used after caesarean section, heparin may increase the frequency of bleeding and wound complications. Originally, UFH was used, but this now appears to have been largely superseded (at least for use in pregnancy and postnatally) by LMWH. The advantages of LMWH over UFH include a longer half‐life (allowing once‐ or twice‐daily subcutaneous dosing), high bioavailability, and predictable anticoagulant response; avoiding the need for dose adjustment, or laboratory monitoring for most women. In addition, LMWHs are understood to have a lower risk of adverse effects such as osteoporosis, and thrombocytopenia (<a href="./references#CD001689-bbs2-0083" title="BauersachsRM . Treatment of venous thromboembolism during pregnancy. Thrombosis Research2009;123(Suppl 2):S45-S50.">Bauersachs 2009</a>). Warfarin is known to cause congenital anomalies (<a href="./references#CD001689-bbs2-0094" title="HallJG , PauliRM , WilsonKM . Maternal and fetal sequelae of anticoagulation during pregnancy. American Journal of Medicine1980;68:122-40.">Hall 1980</a>) and has, therefore, rarely been used in the first trimester or in the last few weeks of pregnancy (<a href="./references#CD001689-bbs2-0083" title="BauersachsRM . Treatment of venous thromboembolism during pregnancy. Thrombosis Research2009;123(Suppl 2):S45-S50.">Bauersachs 2009</a>). Both heparin and warfarin have been used for postnatal thromboprophylaxis, as they are regarded to be safe for mothers who are breastfeeding (<a href="./references#CD001689-bbs2-0083" title="BauersachsRM . Treatment of venous thromboembolism during pregnancy. Thrombosis Research2009;123(Suppl 2):S45-S50.">Bauersachs 2009</a>; <a href="./references#CD001689-bbs2-0100" title="LetskyEA . Peripartum prophylaxis of thromboembolism. Bailliere's Clinical Obstetrics and Gynaecology1997;11:523-43.">Letsky 1997</a>; <a href="./references#CD001689-bbs2-0106" title="OrmeML , LewisPJ , deSwietM , SerlinMJ , SibeonR , BatyJD , et al. May mothers given warfarin breast-feed their infants?British Medical Journal1977;1(6076):1564-5.">Orme 1977</a>). </p> <p>Low‐dose (e.g. 60 mg to 150 mg) aspirin has been widely used in pregnancy in an attempt to prevent the development of pre‐eclampsia (<a href="./references#CD001689-bbs2-0112" title="RobergeS , NicolaidesK , DemersS , HyettJ , ChailletN , BujoldE . The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. American Journal of Obstetrics &amp; Gynecology2017;February:110-120.">Roberge 2017</a>; <a href="./references#CD001689-bbs2-0113" title="RolnikDL , WrightD , PoonLC , O' GormanN , SyngelakA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017;177(7):613-22.">Rolnik 2017</a>; ). Aspirin is usually well‐tolerated and has few adverse effects, and its use for thromboprophylaxis in orthopaedic surgery (<a href="./references#CD001689-bbs2-0109" title="PEP Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Lancet2000;355:1295-302.">PEP Trial 2000</a>) suggests that it may have a role to play in the prevention of VTE in pregnancy (<a href="./references#CD001689-bbs2-0083" title="BauersachsRM . Treatment of venous thromboembolism during pregnancy. Thrombosis Research2009;123(Suppl 2):S45-S50.">Bauersachs 2009</a>). HES has been used for thromboprophylaxis in the past however, it is not commonly prescribed due to concerns about its association with increased risk of anaphylaxis (<a href="./references#CD001689-bbs2-0108" title="PaullJ . A prospective study of dextran-induced anaphylactoid reactions in 5745 patients. Anaesthesia and Intensive Care1987;15:163-7.">Paull 1987</a>). </p> </section> </section> <section id="CD001689-sec-0016"> <h3 class="title" id="CD001689-sec-0016">Why it is important to do this review</h3> <p>This review updates a previously published Cochrane Review on interventions for the prophylaxis of VTE in pregnancy and the early postnatal period (<a href="./references#CD001689-bbs2-0117" title="BainE , WilsonA , TooherR , GatesS , DavisLJ , MiddletonP . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub3]">Bain 2014</a>), which was an update of an earlier version (<a href="./references#CD001689-bbs2-0119" title="TooherR , GatesS , DowswellT , DavisLJ . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub2]">Tooher 2010</a>). Both previous versions of this review concluded that there was insufficient evidence on which to base recommendations for thromboprophylaxis during pregnancy and the early postnatal period, and that large scale randomised controlled trials of currently used interventions should be conducted. </p> <p>Thromboembolic disease, although rare, is a major cause of maternal mortality and morbidity; hence methods of prophylaxis are often used for women at risk. Many methods of prophylaxis carry a risk of adverse effects, and as the risk of VTE is low, it is possible that any benefits of thromboprophylaxis may be outweighed by harm. Current guidelines for clinical practice are based largely on expert opinion, rather than high‐certainty evidence from randomised trials, and guidelines differ in the thromboprophylaxis measures they recommend for women who are pregnant, in birth, or have recently given birth. </p> <p>The current version of the Cochrane Review on prophylaxis for VTE in pregnancy and the early postnatal period (<a href="./references#CD001689-bbs2-0117" title="BainE , WilsonA , TooherR , GatesS , DavisLJ , MiddletonP . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub3]">Bain 2014</a>) searched up to 27 November 2013 and included 19 randomised controlled trials; with 16 trials involving 2529 women contributing data to the review. Additional trials on prophylaxis for VTE have since been performed, which provide new data on the effects of relevant interventions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001689-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001689-sec-0017"></div> <p>To assess the effects of thromboprophylaxis during pregnancy and the early postnatal period in women at increased risk of venous thromboembolism (VTE) on the risk of venous thromboembolic disease and adverse effects. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001689-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001689-sec-0018"></div> <section id="CD001689-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001689-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials comparing any intervention that may prevent venous thromboembolism (VTE) versus placebo or no treatment, or two or more interventions for the prevention of VTE. We excluded quasi‐randomised trials and cross‐over trials, however planned to include cluster‐randomised trials. We included studies reported only as abstracts where it was possible to extract relevant data from the text. When this was not possible, we included these as awaiting assessment studies, pending further publication of their results. </p> </section> <section id="CD001689-sec-0021"> <h4 class="title">Types of participants</h4> <p>Women who were pregnant or had given birth in the previous six weeks, at increased risk of VTE, were included. Women at increased risk were those having/following a caesarean section, with an acquired or inherited thrombophilia, and/or other risk factors for VTE. Women with artificial heart valves were excluded. </p> <p>This is one of a series of Cochrane Reviews assessing the effects of interventions to prevent VTE in women at increased risk of VTE. Thromboprophylaxis has been widely used to prevent miscarriage in women with recurrent pregnancy loss. One Cochrane Review examines effects of aspirin and/or heparin for women with unexplained recurrent miscarriage, with or without thrombophilia (<a href="./references#CD001689-bbs2-0087" title="deJongPG , KaandorpS , Di NisioM , GoddijnM , MiddeldorpS . Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD004734. [DOI: 10.1002/14651858.CD004734]">de Jong 2014</a>). Another evaluates the effects of aspirin or heparin, or both, for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent miscarriage (<a href="./references#CD001689-bbs2-0095" title="HamulyákEN , ScheresLJ , MarijnenMC , GoddijnM , MiddeldorpS . Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD012852. [DOI: 10.1002/14651858.CD012852]">Hamulyák 2020</a>). A further Cochrane Review assesses the effects of antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction (<a href="./references#CD001689-bbs2-0089" title="DoddJM , McLeodA , WindrimRC , KingdomJ . Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD006780. [DOI: 10.1002/14651858.CD006780]">Dodd 2013</a>). To avoid duplication, we therefore have not included studies focused on assessing the effects of aspirin and/or heparin or both on the prevention of miscarriage, or the effects of antithrombotic therapy in women considered at risk of placental dysfunction (not otherwise considered to be at increased risk of VTE). </p> </section> <section id="CD001689-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Any thromboprophylaxis measure (i.e. intervention that may reduce risk of VTE) was eligible, including the following. </p> <p>1. Pharmacological interventions:</p> <p> <ul id="CD001689-list-0003"> <li> <p>unfractionated heparin (UFH);</p> </li> <li> <p>low molecular weight heparin (LMWH);</p> </li> <li> <p>aspirin;</p> </li> <li> <p>warfarin;</p> </li> <li> <p>hydroxyethyl starch (HES);</p> </li> <li> <p>other.</p> </li> </ul> </p> <p>2. Non‐pharmacological interventions:</p> <p> <ul id="CD001689-list-0004"> <li> <p>graduated compression stockings;</p> </li> <li> <p>intermitted pneumatic compression (intermittent compression of the calves during surgery);</p> </li> <li> <p>early mobilisation;</p> </li> <li> <p>surveillance (screening for asymptomatic thromboembolic events to prevent symptomatic deep venous thrombosis (DVT) or pulmonary embolism (PE). </p> </li> </ul> </p> </section> <section id="CD001689-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes were all dichotomous and were measured at the end of the intervention or follow‐up period, as reported by the individual studies. </p> <section id="CD001689-sec-0024"> <h5 class="title">Primary outcomes</h5> <p>1. Maternal death.<br/>2. Symptomatic thromboembolic events.<br/>3. Symptomatic PE.<br/>4. Symptomatic DVT. </p> </section> <section id="CD001689-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>5. Asymptomatic thromboembolic events (detected by screening).<br/>6. Blood transfusion.<br/>7. Bleeding episodes.<br/>8. Serious wound complications (wound infection requiring antibiotics, dehiscence, resuturing).<br/>9. Adverse effects sufficient to stop treatment (undesired harmful effect resulting from the intervention considered serious enough to stop treatment, all author reports).<br/>10. Adverse effects not sufficient to stop treatment (undesired harmful effect resulting from the intervention that was not considered serious enough to stop treatment, all author reports).<br/>11. Symptomatic osteoporosis*.<br/>12. Fetal loss &lt; 20 weeks**.<br/>13. Fetal loss ≥ 20 weeks**.<br/>14. Thrombocytopenia*.<br/>15. Fetal anomalies**. </p> <p>* Mostly applicable for studies involving use of antenatal heparin.</p> <p>** Mostly applicable for studies involving use of antenatal heparin or aspirin.</p> </section> </section> </section> <section id="CD001689-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD001689-sec-0027"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (18 October 2019). We updated this search on 17 February 2021 and added the results to <a href="./references#CD001689-bbs1-0003" title="">Studies awaiting classification</a>. </p> <p>The Register is a database containing over 26,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a>. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD001689-list-0005"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (this includes a Cochrane centralised search feed from WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) ; </p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD001689-bbs1-0001" title="">Included studies</a>, <a href="./references#CD001689-bbs1-0002" title="">Excluded studies</a>, <a href="./references#CD001689-bbs1-0003" title="">Studies awaiting classification</a>, <a href="./references#CD001689-bbs1-0004" title="">Ongoing studies</a>). </p> </section> <section id="CD001689-sec-0028"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (18 October 2019). We updated the search of <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> on 17 February 2021 and added the results to <a href="./references#CD001689-bbs1-0003" title="">Studies awaiting classification</a> (see <a href="./appendices#CD001689-sec-0200">Appendix 1</a> for search methods used). </p> </section> </section> <section id="CD001689-sec-0029"> <h3 class="title" id="CD001689-sec-0029">Data collection and analysis</h3> <p>For methods used in the previous version of this review, see <a href="./references#CD001689-bbs2-0117" title="BainE , WilsonA , TooherR , GatesS , DavisLJ , MiddletonP . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub3]">Bain 2014</a>. </p> <p>For this update, the following methods were used for assessing the reports that were identified as a result of the updated search plus the ongoing, awaiting assessment and relevant excluded studies in the previous version of this review. </p> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD001689-sec-0030"> <h4 class="title">Selection of studies</h4> <p>At least two review authors independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion and where necessary, by involving a third review author. </p> </section> <section id="CD001689-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data (based on the data extraction template of the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth Group</a>). For eligible studies, two review authors extracted the data using the agreed form. We resolved any discrepancies through discussion or, if required, we consulted a third review author. We entered data into Review Manager software (<a href="./references#CD001689-bbs2-0111" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD001689-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001689-bbs2-0096" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). We resolved any disagreement by discussion or by involving a third author. </p> <section id="CD001689-sec-0033"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the methods used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001689-list-0006"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0034"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal the allocation sequence and determined whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001689-list-0007"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0035"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study, the methods, if any, used to blind study participants and personnel from knowledge of which intervention a participant received. We considered studies to be at a low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001689-list-0008"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0036"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD001689-list-0009"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0037"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study and for each outcome or class of outcomes,the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or was supplied by the trial authors, we included missing data in the analyses which we undertook. </p> <p> We assessed the methods as:</p> <p> <ul id="CD001689-list-0010"> <li> <p>low risk of bias (e.g. where there was no missing data or where reasons for missing data were balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0038"> <h5 class="title">(5) Selective reporting bias (checking for reporting bias)</h5> <p>We described for each included study how the possibility of selective outcome reporting bias was examined by us and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001689-list-0011"> <li> <p>low risk of bias (where it was clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review had been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s prespecified outcomes had been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0039"> <h5 class="title">(6) Other sources of bias (checking for bias due to problems not covered by (1) to (5) above) </h5> <p>We described for each included study any important concerns we had about other possible sources of bias. We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD001689-list-0012"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0040"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001689-bbs2-0096" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD001689-sec-0053">Sensitivity analysis</a>.  </p> </section> </section> <section id="CD001689-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <section id="CD001689-sec-0042"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we have presented results as summary risk ratio with 95% confidence intervals.<i> </i> </p> </section> <section id="CD001689-sec-0043"> <h5 class="title">Continuous data</h5> <p>For continuous data, we planned to use the mean difference, if outcomes for which data were combined from trials in meta‐analysis, were measured in the same way by the included trials. We planned to use the standardised mean difference to combine trials that measured the same outcome, but used different methods. </p> </section> </section> <section id="CD001689-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <section id="CD001689-sec-0045"> <h5 class="title">Cluster‐randomised trials</h5> <p>We planned to include cluster‐randomised trials in the analyses along with individually‐randomised trials. We would have adjusted their sample sizes using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001689-bbs2-0096" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) using an estimate of the intra cluster correlation coefficient (ICC) derived from the trial (if possible), from a similar trial, or from a study of a similar population. If we had used ICCs from other sources, we planned to report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we had identified both cluster‐randomised trials and individually‐randomised trials, we planned to synthesise the relevant information. We would have considered it reasonable to combine the results from both if there was little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely. </p> <p>We would have acknowledged heterogeneity in the randomisation unit and performed a subgroup analysis to investigate the effects of the randomisation unit. </p> </section> <section id="CD001689-sec-0046"> <h5 class="title">Cross‐over trials</h5> <p>We considered cross‐over designs inappropriate for this research question.</p> </section> <section id="CD001689-sec-0047"> <h5 class="title">Multiple‐armed trials</h5> <p>We combined relevant groups in the multi‐arm trials or included relevant arms as separate comparisons, to create appropriate single pair‐wise comparisons for inclusion in the review analyses, thereby avoiding unit of analysis errors. </p> </section> </section> <section id="CD001689-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> <p>In future updates of this review, if we include any studies where women were recruited preconception, for outcomes relating to pregnancy, we plan to take a pragmatic approach and include in the denominators only those women known to have become pregnant. </p> </section> <section id="CD001689-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial where an I² was greater than 30% and either a Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.<b> </b> </p> </section> <section id="CD001689-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates of this review, if there are 10 or more studies in meta‐analyses we plan to investigate reporting biases (such as publication bias) using funnel plots. We plan to assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD001689-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD001689-bbs2-0111" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data, as it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar. Had there been clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or where substantial statistical heterogeneity was detected, we planned to use random‐effects meta‐analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. We would have treated the random‐effects summary as the average range of possible treatment effects and we would have discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not considered clinically meaningful, we would not have combined trials. </p> <p>If we had used random‐effects analyses, we would have presented the results as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I². </p> <p>We summarised results for 13 intervention comparisons under the following four main headings, based on the intervention time points antenatal ± postnatal, intrapartum + postnatal, postnatal, and the distinction between type of delivery in the intrapartum and postnatal interventions assessed: </p> <p> <ul id="CD001689-list-0013"> <li> <p>antenatal (± postnatal) prophylaxis;</p> </li> <li> <p>peripartum prophylaxis (vaginal birth or caesarean);</p> </li> <li> <p>peripartum/postpartum prophylaxis (caesarean);</p> </li> <li> <p>postnatal prophylaxis.</p> </li> </ul> </p> </section> <section id="CD001689-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out subgroup analyses based on:</p> <p> <ul id="CD001689-list-0014"> <li> <p>risk factors for VTE (i.e. previous VTE versus family history of VTE versus inherited or acquired thrombophilia versus emergency or elective caesarean section, with or without other risk factors versus other risk factors). </p> </li> </ul> </p> <p>We planned to restrict subgroup analyses to the primary review outcomes. We planned to assess subgroup differences by interaction tests available within RevMan (<a href="./references#CD001689-bbs2-0111" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value. However, we were unable to conduct subgroup analyses in this update due to lack of data. We will include these analyses in future versions of the review if the necessary data become available. There was no heterogeneity observed. </p> </section> <section id="CD001689-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to explore the effects of trial quality by omitting trials rated 'high' or 'unclear' risk of selection bias (allocation concealment and sequence generation) or attrition bias, restricting these analyses to the primary outcomes. We were able to conduct these analyses for three of the13 review comparisons, and three of the five primary review outcomes (symptomatic thromboembolic events, symptomatic PE, and symptomatic DVT), using data from nine trials. </p> </section> <section id="CD001689-sec-0054"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>For this update we assessed the certainty of the evidence where possible (data allowed) using the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a>, including the main comparisons (all comparisons of heparin (LMWH or UFH) versus no treatment/placebo, and LMHW versus UFH) and the following five outcomes, selected due to their importance (potential to change practise): </p> <p> <ol id="CD001689-list-0015"> <li> <p>maternal death;</p> </li> <li> <p>symptomatic thromboembolic events;</p> </li> <li> <p>symptomatic PE;</p> </li> <li> <p>symptomatic DVT;</p> </li> <li> <p>adverse effects sufficient to stop treatment.</p> </li> </ol> </p> <p>The <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool was used to import data from Review Manager 5.4 (<a href="./references#CD001689-bbs2-0111" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014.">RevMan 2014</a>) in order to create ’Summary of findings’ tables. A summary of the intervention effect and a measure of certainty for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence for each outcome. The evidence can be downgraded from 'high certainty' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001689-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001689-sec-0055"></div> <section id="CD001689-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD001689-sec-0057"> <h4 class="title">Results of the search</h4> <p>In the previous version of the review (<a href="./references#CD001689-bbs2-0117" title="BainE , WilsonA , TooherR , GatesS , DavisLJ , MiddletonP . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub3]">Bain 2014</a>), 19 trials (32 reports) were included, 23 studies were excluded, eight studies (13 reports) were assessed as ongoing, and two reports were classified awaiting further classification. Updated searches of the Cochrane Pregnancy and Childbirth’s Trials Register on 18 October 2019 identified 39 new records; additional searching found five new records. For this update we assessed these new records, plus the two awaiting classification study records and 13 ongoing study records from <a href="./references#CD001689-bbs2-0117" title="BainE , WilsonA , TooherR , GatesS , DavisLJ , MiddletonP . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub3]">Bain 2014</a>. </p> <p>We included 10 new trials (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>), and excluded 10 studies (<a href="./references#CD001689-bbs2-0030" title="AinaA , NCT00356434. Study of patient compliance and comfort using sequential compression devices and foot pumps for DVT prevention. https://clinicaltrials.gov/ct2/show/results/NCT00356434 (first received 26 July 2006). ">Aina 2006</a>; <a href="./references#CD001689-bbs2-0031" title="AlalafA , NCT01588171. Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. https://clinicaltrials.gov/ct2/show/NCT01588171 (first received 30 April 2012). AlalafSK , JawadRK , MuhammadPR , AliMS , Al TawilNG . Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. BMC Pregnancy &amp; Childbirth2015;15:72. ">Alalaf 2015</a>; <a href="./references#CD001689-bbs2-0035" title="deJongPG , QuenbyS , BloemenkampKW , Braams-LismanBA , deBruinJP , CoomarasamyA , et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. Trials2015;16(1):208. ">de Jong 2015</a>; <a href="./references#CD001689-bbs2-0041" title="GuvenD , BakayK , KocakI , OzdemirA . Effectiveness of bemiparin sodium for preventing pregnancy loss in patients with MTHFR C677T mutation and habitual abortus. Open Journal of Obstetrics and Gynecology2014;4:930-4. ">Guven 2014</a>; <a href="./references#CD001689-bbs2-0047" title="LangerE , FiedlerA , SchleusnerE , SchlembachD . Placental volume in women under treatment with recurrent miscarriages. Ultraschall in der Medizin, Supplement2013;34(Suppl 1):WS_SL6_05. ">Langer 2013</a>; <a href="./references#CD001689-bbs2-0048" title="LaskinCA , NCT00564174. A randomized controlled trial comparing low molecular weight heparin and aspirin to aspirin alone in women with unexplained recurrent pregnancy loss. https://clinicaltrials.gov/ct2/show/NCT00564174 (first received 27 November 2007). LaskinCA , SpitzerKA , ClarkCA , CrowtherMR , GinsbergJS , HawkerGA , et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. Journal of Rheumatology2009;36(2):279-87. ">Laskin 2007</a>; <a href="./references#CD001689-bbs2-0049" title="MilicD , ZivicS , BogdanovicD , JovanovicM . Compression stockings in the prevention of venous disorders in pregnancy. Phlebology2018;33(10):709. ">Milic 2018</a>; <a href="./references#CD001689-bbs2-0055" title="RodgerM , NCT03100123. A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin versus low-molecular-weight heparin (lmwh) and aspirin in women with antiphospholipid syndrome and pregnancy loss. https://clinicaltrials.gov/ct2/show/NCT03100123 (first received 4 April 2017). ">Rodger 2017</a>; <a href="./references#CD001689-bbs2-0056" title="SamanthaP , BarillariG , VenturelliU , TurelloM . Thromboprophylaxis with two different dosages of lmwh (calcic nadroparin) in pregnant women with thrombophilia: a single center experience. Journal of Thrombosis and Haemostasis2013;11:96-7. ">Samantha 2013</a>; <a href="./references#CD001689-bbs2-0057" title="SchleussnerE , KaminG , SeligerG , RogenhoferN , EbnerS , TothB , et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Annals of Internal Medicine2015;162(9):601-9. ">Schleussner 2015</a>). Seven studies are listed as ongoing (<a href="./references#CD001689-bbs2-0070" title="DargaudY , NCT03659708. Prospective multicentre randomized clinical trial on the management of pregnancies with high risk of venous thrombosis. https://clinicaltrials.gov/ct2/show/NCT03659708 (first received 6 September 2018). ">Dargaud 2018</a>; <a href="./references#CD001689-bbs2-0071" title="HellerJ . Compression stocking use in multiparous women during pregnancy &amp; its effects on chronic venous insufficiency. Phlebology2016;31(2 Suppl):42-3. ">Heller 2016b</a>; <a href="./references#CD001689-bbs2-0072" title="NCT00225108. The STOP CLOT pilot study: study of low molecular weight heparin in high risk postpartum women following cesarean section (ongoing trial). http://clinicaltrials.gov/show/NCT00225108 (first received 21 March 2006). ">NCT00225108</a>; <a href="./references#CD001689-bbs2-0073" title="NCT00878826. Prophylactic enoxaparin dosing for prevention of venous thromboembolism in pregnancy. http://clinicaltrials.gov/ct2/show/record/NCT00878826 (first received 31 March 2013). ">NCT00878826</a>; <a href="./references#CD001689-bbs2-0074" title="NCT01019655. Heparin for pregnant with thrombophilia. http://clinicaltrials.gov/show/NCT01019655 (first received 29 July 2012). ">NCT01019655</a>; <a href="./references#CD001689-bbs2-0075" title="BistervelsI , BlekerS , MiddeldorpS , BuchmullerA , DecoususH , ChauleurC , et al. Induced delivery and neuraxial anesthesia in pregnant women using thromboprophylaxis: data from the highlow study. Research and Practice in Thrombosis and Haemostasis2017;1:41-2. BistervelsI , BuchmüllerA , BlekerS , ChauleurC , Ni AinleF , DonnellyJ , et al. Neuraxial anesthesia in pregnant women using thrombosis prophylaxis: data from the Highlow study. Thrombosis Research2017;Conference: 7th International Symposium on Women's Health Issues in Thrombosis and Haemostasis. Spain. 151(Suppl 1):S131-2. BistervelsI , BuchmullerA , Ni AinleF , BlekerS , ChauleurC , DonnellyJ , et al. Management of anticoagulant therapy around delivery: results from the ongoing highlow study. Research and Practice in Thrombosis and Haemostasis2019;3:866-7. [CENTRAL: CN-01978640] [EMBASE: 628813887]BlekerSM , BuchmullerA , ChauleurC , AinleFN , DonnellyJ , VerhammeP , et al. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. Thrombosis Research2016;144:62-8. BlekerSM , IngridBM , BuchmullerA , ChauleurC , AinleFN , DonnellyJ , et al. Interim report of the highlow study: a randomized controlled trial comparing two doses of low molecular weight heparin for the prevention of pregnancy-associated recurrent venous thromboembolism. Blood2016;128(22):1444. EUCTR2012-001505-24-ES. Highlow study: prevention of recurrent deep vein thrombosis and lung embolism in pregnant women [Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses - Highlow study]. Http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-001505-24-ES (first received 2018). [CENTRAL: CN-01905819] NCT01828697. Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses. http://clinicaltrials.gov/ct2/show/NCT01828697 (first received 21 May 2013). ">NCT01828697</a>; <a href="./references#CD001689-bbs2-0076" title="NCT04153760. Pilot PARTUM Trial: Postpartum Aspirin to reduce thromboembolism undue morbidity (PARTUM). https://clinicaltrials.gov/ct2/show/NCT04153760 (first received 19 August 2020). ">NCT04153760</a>); and two studies (<a href="./references#CD001689-bbs2-0063" title="DittmerU , RathW , SchraderJ , ZuchnerC , SchelerF , KuhnW . Prevention of deep vein thrombosis (DVT) in pregnancy, after caesarean section and after gynaecological abdominal surgery. A comparison between low molecular weight heparin (LMW) and standard heparin (UFH) [abstract]. Annals of Haematology1991;62 Suppl 1:A40. ">Dittmer 1991</a>; <a href="./references#CD001689-bbs2-0066" title="NagornayaV , GontaR , NickolayK , PokhilchenkoM . The risk of venous thromboembolism and its prevention in obstetrics. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S796. ">Nagornaya 2012</a>) remain awaiting classification. See <a href="#CD001689-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD001689-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD001689-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We updated the search in February 2021 and identified 10 trial reports. Two of these are additional reports of an ongoing study (<a href="./references#CD001689-bbs2-0075" title="BistervelsI , BlekerS , MiddeldorpS , BuchmullerA , DecoususH , ChauleurC , et al. Induced delivery and neuraxial anesthesia in pregnant women using thromboprophylaxis: data from the highlow study. Research and Practice in Thrombosis and Haemostasis2017;1:41-2. BistervelsI , BuchmüllerA , BlekerS , ChauleurC , Ni AinleF , DonnellyJ , et al. Neuraxial anesthesia in pregnant women using thrombosis prophylaxis: data from the Highlow study. Thrombosis Research2017;Conference: 7th International Symposium on Women's Health Issues in Thrombosis and Haemostasis. Spain. 151(Suppl 1):S131-2. BistervelsI , BuchmullerA , Ni AinleF , BlekerS , ChauleurC , DonnellyJ , et al. Management of anticoagulant therapy around delivery: results from the ongoing highlow study. Research and Practice in Thrombosis and Haemostasis2019;3:866-7. [CENTRAL: CN-01978640] [EMBASE: 628813887]BlekerSM , BuchmullerA , ChauleurC , AinleFN , DonnellyJ , VerhammeP , et al. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. Thrombosis Research2016;144:62-8. BlekerSM , IngridBM , BuchmullerA , ChauleurC , AinleFN , DonnellyJ , et al. Interim report of the highlow study: a randomized controlled trial comparing two doses of low molecular weight heparin for the prevention of pregnancy-associated recurrent venous thromboembolism. Blood2016;128(22):1444. EUCTR2012-001505-24-ES. Highlow study: prevention of recurrent deep vein thrombosis and lung embolism in pregnant women [Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses - Highlow study]. Http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-001505-24-ES (first received 2018). [CENTRAL: CN-01905819] NCT01828697. Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses. http://clinicaltrials.gov/ct2/show/NCT01828697 (first received 21 May 2013). ">NCT01828697</a>), one is an additional report of <a href="./references#CD001689-bbs2-0040" title="GrisJC , ChauleurC , MaresP , NouvellonE , MercierE , BouvierS , et al. Enoxaparin for the secondary prevention of placental complications in women with previous severe pre-eclampsia: the pilot randomised controlled NOH-PE study. Journal of Thrombosis and Haemostasis : JTH2011;9(Suppl 2):753. GrisJC , ChauleurC , MolinariN , MaresP , Fabbro-PerayP , QuereI , et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: the pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis2011;106(6):1053-61. ">Gris 2011</a>, and six trials (seven reports) are awaiting further classification (<a href="./references#CD001689-bbs2-0062" title="AbdolvandM , AleyasinA , JavadiMR , SolduzianM , HosseiniSH , ZiaeiZ , et al. Comparison of efficacy and safety of two different enoxaparin products in prevention of venous thromboembolism following major obstetric-gynecological surgeries: an open-label randomized clinical trial. Iranian Journal of Pharmaceutical Research2019;18(4):2172-9. [CENTRAL: CN-02074323] [EMBASE: 2003440151]">Abdolvand 2019</a>; <a href="./references#CD001689-bbs2-0064" title="Ganer HermanH , KleinerI , TairyD , GonenN , Ben ZviM , KovoM , et al. Effect of digital step counter feedback on mobility after cesarean delivery: a randomized controlled trial. Obstetrics and Gynecology2020;135(6):1345-52. [CENTRAL: CN-02131345] [EMBASE: 631910090] [PMID: 32459426]HermanHG , KleinerI , TairyD , GonenN , BenZM , KovoM , et al. 623: improving post-Cesarean mobility with personalized feedback using digital step counters - a randomized controlled trial. American Journal of Obstetrics and Gynecology2020;222(1):S397-8. [CENTRAL: CN-02075395] [EMBASE: 2004455439]">Ganer 2020</a>; <a href="./references#CD001689-bbs2-0065" title="MovahediM , MotamediM , SajjadiehA , BahramiP , SaeediM . Pregnancy outcome in women with mechanical prosthetic heart valves at their first trimester of pregnancy treated with unfractionated heparin (UFH) or enoxaparin: a randomized clinical trial. Journal of Cardiovascular and Thoracic Research2020;12(3):209-13. [CENTRAL: CN-02194966] [EMBASE: 632980316] [PMID: 33123327]">Movahedi 2020</a>; <a href="./references#CD001689-bbs2-0067" title="NCT02856295. anti10a levels in women treated with LMWH in the postpartum period. Https://clinicaltrials.gov/show/NCT02856295 (first received 2016 August 04). [CENTRAL: CN-01592274] ">NCT02856295</a>; <a href="./references#CD001689-bbs2-0068" title="NCT04305756. Impact of prophylactic low-molecular weight heparin dosing on clotting parameters following cesarean delivery. Https://clinicaltrials.gov/show/NCT04305756 (first received 2020 March 12). [CENTRAL: CN-02089003] ">NCT04305756</a>; <a href="./references#CD001689-bbs2-0069" title="NCT04635839. Heparin Prophylaxis Dosing for antepartum hospitalizations (HEPDOSE). Https://clinicaltrials.gov/show/NCT04635839 (first received 2020 Nov 19). [CENTRAL: CN-02205733] ">NCT04635839</a>. </p> <p>In summary, the current review update includes: a total of 29 studies (66 reports or 62 unique reports (<a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a> and <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a> have three references in common and <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> have one reference in common)); 32 excluded studies (38 reports); seven ongoing studies (13 reports); and eight studies (nine reports) in awaiting classification. </p> </section> <section id="CD001689-sec-0058"> <h4 class="title">Included studies</h4> <p>A total of 29 trials (involving 3839 women) (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>) are included in this review update. Two of the trials (<a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>) reported no relevant outcome data, and thus 27 studies contribute to quantitative analyses. All of the included studies were individually‐randomised trials. Three of the trials each had three arms (<a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>). </p> <p><a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> and <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> are both part of the 'FRUIT RCT' ‐ with <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> recruiting women with antiphospholipid antibodies. </p> <p>Of the 27 trials contributing data for the review analysis, 11 assessed <b>antenatal (± postnatal)</b> <b>prophylaxis</b>, with five assessing heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH)) versus no treatment or placebo (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>); four assessing LMWH versus UFH (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>), one assessing adjusted‐dose versus fixed‐dose LMWH (<a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>), and one assessing compression stockings versus none (<a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>). Fourteen trials assessed <b>peripartum/postnatal</b> <b>prophylaxis</b>, with one trial assessing UFH versus no treatment, in women having a vaginal or caesarean birth (<a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>); and the remaining 13 trials assessing interventions in women having a caesarean birth; including five assessing heparin (LMWH or UFH) versus no treatment or placebo (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>), one assessing hydroxyethyl starch (HES) versus UFH (<a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>), three assessing LMWH versus UFH (<a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>), one assessing five‐ versus 10‐day LMWH (<a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>), one assessing weight‐based versus fixed‐dose LMWH (<a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>), one assessing LMWH versus LMWH (different types) (<a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>), and one assessing compression devices versus bed rest (<a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>). The remaining two trials (<a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> and <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>), assessed <b>postnatal prophylaxis</b>, comparing LMWH with no treatment or placebo. Therefore, 13 comparisons of thromboprophylaxis in pregnancy and the early postnatal period (first six weeks after birth), were included in this review. </p> <p>The included trials have been published over four decades ‐ from 1975 to 2016.</p> <p>For further details, see <a href="./references#CD001689-sec-0215" title="">Characteristics of included studies</a> and <a href="#CD001689-tbl-0007">Table 1</a>. </p> <div class="table" id="CD001689-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions and studies in each comparison</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i><b>Antenatal (± postnatal)</b> </i><b>prophylaxis</b> (n = 11 RCTs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 1</b> ‐ Heparin (LMWH or UFH) versus no treatment or placebo </p> <p><a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 2</b> ‐ LMWH versus UFH </p> <p><a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 3</b> ‐ Adjusted‐ versus fixed‐dose LMWH </p> <p><a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 4</b> ‐ Compression stockings versus none </p> <p><a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i><b>Peripartum/postnatal</b> </i><b>prophylaxis</b> (n = 14 RCTs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaginal birth or caesarean</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 5</b> ‐ UFH versus no heparin treatment </p> <p><a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Caesarean</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 6</b> ‐ Heparin (LMWH or UFH) versus no treatment or placebo </p> <p><a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 7</b> ‐ HES versus UFH </p> <p><a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 8</b> ‐ LMWH versus UFH </p> <p><a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>*; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>*; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 9</b> ‐ 5‐day versus 10‐day LMWH </p> <p><a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 10</b> ‐ Weight‐based versus fixed‐dose LMWH </p> <p><a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 11</b> ‐ LMWH versus LMWH (different types) </p> <p><a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>* </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 12</b> ‐ Compression devices versus bed rest </p> <p><a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Postnatal prophylaxis</b> (n = 2 RCTs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison 13 ‐ LMWH versus no treatment or placebo</p> <p><a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Trial had three arms. <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a> assessed three different types of heparin, and we included all three groups in the review analysis as pair‐wise comparisons; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a> included two separate LMWH groups and an UFH group, and for this trial we combined the two LMWH groups in the review meta‐analysis. <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a> included two randomised treatment groups, and a non‐randomised control (no treatment group), so for this trial we included only the two treatment groups. </p> <p>Two additional studies are included in the review (<a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>), both of which assessed intrapartum (+ postnatal) prophylaxis (pharmacologic), although are not included in the review comparisons as they contributed no outcomes for analysis. </p> <p>Abbreviations: <b>RCT</b> : randomised controlled trial; <b>LMWH</b> : low molecular weight heparin; <b>UF</b>: unfractionated heparin </p> </div> </div> <section id="CD001689-sec-0059"> <h5 class="title">Settings</h5> <p>Almost all of the 29 trials were conducted in high‐income countries. Six were conducted in the UK (<a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>), and six in the USA (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0058" title="StephensonMD , BallemPJ , TsangP , PurkissS , EnsworthS , HoulihanE , et al. Treatment of antiphospholipid antibody syndrome (aps) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of Obstetrics and Gynaecology Canada2004;26(8):729-34. ">Stephenson 2004</a>). Of the remaining 17 trials, three were conducted in Germany (<a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>), two in Israel (<a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>), and one each in Australia (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>), Saudi Arabia (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>), Spain (<a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>), Ireland (<a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>), Finland (<a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>), and Switzerland (<a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). Five trials were performed in more than one country: <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> (Australia, Sweden, the Netherlands); <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a> (Australia, Canada, France, UK, USA); <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> (Australia, Sweden); and <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> and <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> (both Canada and USA). The study setting for <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a> was unclear (though the authors reported that they were from Belgium). </p> </section> <section id="CD001689-sec-0060"> <h5 class="title">Participants</h5> <p>All participants in the trials were women who were pregnant, giving birth or who had given birth in the previous six weeks and were judged to be at increased risk of venous thromboembolism (VTE). The number of women randomised varied widely across the trials, however most trials were relatively small. <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a> and <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a> were the two smallest trials, randomising 16 and 17 women, respectively. The two trials evaluating postnatal prophylaxis randomised only 25 women (<a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>) and 37 women (<a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>). <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>, which randomised 646 women, and <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>, which randomised 580 women, were the largest trials. </p> <p>Characteristics of the included women are summarised below, including age, personal history of VTE, thrombophilia, pre‐eclampsia, obesity, and caesarean type (elective versus emergency, relevant for the trials assessing prophylaxis in women scheduled for, undergoing, or after caesarean birth). For further details see <a href="#CD001689-tbl-0008">Table 2</a>. </p> <div class="table" id="CD001689-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Personal history of VTE</b> </p> <p><b>(all/none/mixed NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Known acquired or inherited thrombophilia</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Obesity (BMI ≥ 30 kg/m<sup>2</sup>)</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Advanced age (e.g. ≥ 35 years)</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pre‐eclampsia</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>If post caesarean prophylaxis (emergency/elective/mixed/NR)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (though "Need of therapy with an anticoagulant" was listed as an exclusion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (only reports that "Any patient who was a candidate for low‐dose thromboprophylaxis" were included) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (women with known coagulation or bleeding disorders were excluded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (based on discussion, and apparent exclusion of women with pre‐eclampsia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (only reports that "women... who had not required prophylaxis or treatment with any type of LMWH during pregnancy (low risk of VTE during pregnancy)" were included) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (based on baseline characteristics reported ‐ only reported pregnancy‐induced hypertension) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/mixed (only reports booking weight ≥ 80 kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/mixed (only reports booking weight ≥ 80 kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (women "undergoing caesarean section were recruited to the study if this procedure was performed as an emergency... or if they had 1 or more of the other defined risk factors for thromboembolic disease"; "Additional risk factors include advanced maternal age, high parity, obesity, pre‐eclampsia and prolonged bed rest before delivery"; however, no baseline characteristics detailed). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (1 woman in HES group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/mixed/none (1 woman in LMWH group had BMI &gt; 26 kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (women with coagulation disorders were excluded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/none (women with pregnancy‐induced hypertension were excluded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/none? (reported as an outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/none? (reported as an outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (vaginal births also included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (vaginal births also included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: <b>BMI</b> : body mass index;<b>HES</b> : hydroxyethyl starch; <b>LMWH:</b> low molecular weight heparin; <b>NR</b> : not reported; <b>NA</b> : not applicable; <b>VTE</b>: venous thromboembolism </p> <p>*No outcomes included in the review analyses.</p> </div> </div> <section id="CD001689-sec-0061"> <h6 class="title">Age</h6> <p>Nineteen of the 29 trials (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>), included a mix of women of advanced age (≥ 35 years) and younger women. In one trial (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>), no women older than 35 years were included. In the remaining nine trials, due to limited information provided, age ranges of women were unclear (<a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>). </p> </section> <section id="CD001689-sec-0062"> <h6 class="title">Personal history of venous thromboembolism (VTE</h6> <p>In six of the included trials, a mix of women with and without a personal history of VTE were included (<a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>). In eight trials none of the women had a personal history of VTE (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>), and in two trials all women had a personal history of VTE (<a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>). In the remaining 13 trials, personal history of VTE was not reported (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). </p> </section> <section id="CD001689-sec-0063"> <h6 class="title">Thrombophilia (acquired or inherited)</h6> <p>In six trials all the women included had acquired or inherited thrombophilia (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>). In four trials none of the included women had thrombophilia (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>). Six trials included women with and without thrombophilia (<a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>). However, participant thrombophilia status was poorly reported. Authors of 10 trials provided insufficient information to determine thrombophilia status (<a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). In the remaining three trials, whilst this was not clearly reported, information provided suggests that two (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>) included no women with thrombophilia, and one (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>) included some women with thrombophilia. </p> </section> <section id="CD001689-sec-0064"> <h6 class="title">Pre‐eclampsia</h6> <p>Pre‐eclampsia status of women in the included trials was also poorly reported. In five of the 29 trials, authors reported that no women had pre‐eclampsia (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>). In two trials (<a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>) pre‐eclampsia was reported as a study outcome (thus it may be assumed that no women had pre‐eclampsia at baseline). In the <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a> trial, it is likely that none of the women had pre‐eclampsia (although this is not stated), as women with pregnancy‐induced hypertension were not eligible. In eight trials it is clear that women with and without pre‐eclampsia were included (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>). In the remaining 13 trials the pre‐eclampsia status of women was unclear due to insufficient information (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). </p> </section> <section id="CD001689-sec-0065"> <h6 class="title">Obesity</h6> <p>One trial (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>) included no obese women and one trial (<a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>) included only obese women. In 14 trials a mix of obese women, and women of other weight categories were included (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>). In the remaining 13 trials (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>;<a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>), the weight status of women was unclear. </p> </section> <section id="CD001689-sec-0066"> <h6 class="title">Emergency versus elective caesarean</h6> <p>Seventeen of the 29 trials, assessed thromboprophylaxis in women having a caesarean (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). Four trials included women undergoing elective caesarean birth only (<a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>). In one trial (<a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>), the status of included caesarean section births (emergency/elective) was unclear. In the remaining 12 trials, women scheduled for, undergoing, or who had an emergency or elective caesarean surgery were included. </p> </section> </section> <section id="CD001689-sec-0067"> <h5 class="title">Interventions</h5> <p>Eleven of the 29 trials assessed antenatal (± postnatal) thromboprophylaxis, with 10 assessing pharmacological interventions (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>), and one assessing a mechanical intervention (compression stockings) (<a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>). Sixteen trials assessed peripartum/postnatal thromboprophylaxis (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). All except one (<a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>), were in women having a caesarean birth, and all but one (<a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>), assessed pharmacological interventions. The remaining two trials assessed postnatal thromboprophylaxis (<a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>), and pharmacological interventions (following vaginal or caesarean birth). </p> <p>The interventions assessed by each trial are briefly described below.</p> <section id="CD001689-sec-0068"> <h6 class="title">Antenatal (± postnatal) prophylaxis</h6> <p>Heparin (LMWH or UFH) versus no treatment or placebo (Comparison 1).</p> <p> <ul id="CD001689-list-0016"> <li> <p><a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> assessed once‐daily weight‐adjusted LMWH (dalteparin (fragmin) 5000 international units (IU) subcutaneously starting between six and 12 weeks' gestation up to the onset of labour; combined with 80 mg oral aspirin daily), starting before 12 weeks' gestation, and continued until 36 weeks' gestation (Australian participants received 100 mg aspirin; Swedish participants received 75 mg aspirin), compared with antenatal aspirin daily (80 mg orally, from 12 to 26 weeks' gestation). All women received weight‐adjusted LMWH (dalteparin) in the early postpartum period. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a> assessed once‐daily subcutaneous 40 mg enoxaparin (LMWH) from antenatal recruitment until a maximum of six weeks after birth, versus once‐daily subcutaneous placebo (same timing). </p> </li> <li> <p><a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a> assessed subcutaneous antenatal UFH throughout pregnancy (calcium, 10,000 IU twice daily, commencing shortly after the first antenatal visit) and UFH for six weeks postpartum (8000 IU twice daily) compared with no antenatal heparin and the same postpartum UFH treatment. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a> assessed antepartum LMWH (dalteparin 5000 IU once daily by subcutaneous self‐injection from the day of randomisation until 20 weeks' gestation followed by 5000 IU twice daily from 20 weeks until at least 37 weeks' gestation), compared with placebo. All participants received postpartum dalteparin (5000 IU daily) by subcutaneous self‐injection starting six to 28 hours after birth until day 42. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> assessed the same intervention as the <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> trial in a different population. </p> </li> </ul> </p> <p>LMWH versus UFH (Comparison 2)</p> <p> <ul id="CD001689-list-0017"> <li> <p><a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a> assessed self‐administered enoxaparin sodium (30 mg twice daily, starting from before 24 weeks up to 28 weeks' gestation, then 40 mg twice daily until birth), versus heparin sodium (7500 units twice daily, starting before 24 weeks until 28 weeks, then 10,000 units twice daily until birth). All women received adjusted‐dose coumadin for six to eight weeks after birth. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a> assessed dalteparin (initial dosing 2500 IU (5000 IU if &gt; 70 kg) subcutaneously once daily then increased to a maximum of 10,000 IU/day to maintain alpha‐Factor Xa levels at 0.1 to 0.3 IU/mL), compared with UFH (women were dosed with the standard 5000 IU (8000 IU if &gt; 68 kg) subcutaneously twice daily) (intervention start time not reported). </p> </li> <li> <p><a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a> dose‐adjusted heparin (adjusted to maintain an anti‐Xa (heparin assay) level between 0.03 to 0.05 U/mL) versus UFH, with women in both groups also prescribed daily aspirin (81 mg) (intervention not further specified in the conference abstract) (intervention start time and duration not reported). </p> </li> <li> <p><a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a> assessed subcutaneous antenatal plus postnatal dalteparin (Fragmin, once daily starting at 20 weeks' gestation, with a starting dose of 5000 IU (women weighing &lt; 85 kg) or 7500 IU (women weighing ≥ 85 kg), dose adjusted based on anti‐Xa measurements; during birth, 2500 IU dalteparin was administered 18 hours after the previous dose if the woman had not yet given birth; if she gave birth within 18 hours, 5000 IU was given 24 hours after the previous injection; the daily dose postpartum, for six weeks, was 2500 IU lower than during the third trimester; and two weeks after birth, if anti‐Xa was &lt; 0.20, the dose was increased by 2500 IU), versus subcutaneous UFH (7500 IU, adjusted according to the activated partial thromboplastin time (APTT) target values, twice daily starting at 20 weeks' gestation and for six weeks postpartum; at the time of birth, and on the first day postpartum 7500 IU UFH was given at 12‐hour intervals, and then according to APTT target values). </p> </li> </ul> </p> <p>Adjusted‐dose versus fixed‐dose LMWH (Comparison 3)</p> <p> <ul id="CD001689-list-0018"> <li> <p><a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a> assessed antepartum enoxaparin according to the results of anti‐FXa levels (initial dose of 40 mg, increased by fractions of 20 mg according to anti‐FXa level with targeted prophylactic level 0.2 IU/mL or more 3.5 to 4 hours post‐injection) versus a fixed antenatal daily dose of enoxaparin (40 mg daily, by subcutaneous self‐injection) regardless of the results of anti‐factor Xa, until birth. All women were prescribed enoxaparin (40 mg once daily by subcutaneous injection) from day one until day 42 after birth. </p> </li> </ul> </p> <p>Compression stockings versus none (Comparison 4)</p> <p> <ul id="CD001689-list-0019"> <li> <p><a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> assessed advice to wear 20 to 30 mm Hg maternity pantyhose versus no such advice (intervention timing unclear, although authors report that women were visited three times, between eight to 20 weeks, and 32 ± 4 weeks before the birth, plus at eight weeks postpartum±2 weeks). </p> </li> </ul> </p> </section> <section id="CD001689-sec-0069"> <h6 class="title">Peripartum/postnatal prophylaxis</h6> <section id="CD001689-sec-0070"> <p><b>Vaginal birth or caesarean</b></p> <p>UFH versus no treatment (Comparison 5)</p> <p> <ul id="CD001689-list-0020"> <li> <p><a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a> assessed subcutaneous UFH (50 mg (5000 IU) every 12 hours for four to five days after birth, about two‐thirds of women having a vaginal birth had the first dose in active labour and a third after birth; for women having a caesarean section UFH was given two hours before surgery, at the end of surgery, and at 12‐hour intervals; for women having an emergency caesarean, the initial dose was immediately following the decision), versus standard care/no treatment. </p> </li> </ul> </p> </section> <section id="CD001689-sec-0071"> <p><b>Caesarean</b></p> <p>Heparin (LMWH or UFH) versus no treatment or placebo (Comparison 6)</p> <p> <ul id="CD001689-list-0021"> <li> <p><a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a> assessed tinzaparin (4500 IU subcutaneously once daily), starting from 12 to 24 hours after caesarean section continuing for two weeks, compared with placebo. All women in this trial also received non‐pharmacological prophylaxis using graduated compression stockings. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a> assessed dalteparin (2500 IU once daily) versus placebo (saline) once daily for four to five days, with the interventions starting four to 24 hours after caesarean section. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a> assessed once‐daily self‐injected subcutaneous 40 mg enoxaparin in 1 mL versus once‐daily self‐injected subcutaneous placebo (normal saline 1 mL). Treatment with the study drug began within 12 hours of the caesarean section, and its duration was determined by the attending clinician. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a> assessed UFH 1000 units, one hour before caesarean, then twice daily for five days versus placebo (saline) one hour before caesarean, then twice daily for five days. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a> assessed twice‐daily subcutaneous 5000 IU heparin (UFH) with physiotherapy versus physiotherapy without heparin (intervention timing unclear). </p> </li> </ul> </p> <p>HES versus UFH (Comparison 7)</p> <p> <ul id="CD001689-list-0022"> <li> <p><a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a> assessed HES 6%, 3 x 500 mL (first 500 mL administered during the caesarean, second in the evening of the day of the operation, third in the evening of the first postoperative day), versus UFH 5000 IU (first dose two hours after the operation followed by every eight hours for seven days). </p> </li> </ul> </p> <p>LMWH versus UFH (Comparison 8)</p> <p> <ul id="CD001689-list-0023"> <li> <p><a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>** assessed enoxaparin 20 mg once daily versus enoxaparin 40 mg once daily versus UFH 7500 IU every 12 hours, with each of the interventions starting after the caesarean section (duration of intervention unclear). </p> </li> <li> <p><a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>** assessed dalteparin 5000 IU/daily for seven days post operatively, with the first dose six hours following caesarean section and then at 24‐hourly intervals versus calciparin 2 x 5000 IU daily, with the first dose six hours following caesarean section, (and then at eight‐hour intervals) versus no pharmacological prophylaxis but compression stockings according to the guidelines during hospital days (third group not randomly assigned and excluded in this review). </p> </li> <li> <p><a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a> assessed fragmin (2500 to 5000 anti‐Xa units) once daily versus 5000 units UFH (Liquemin) + 500 mL dextran 60 administered two to three times daily with treatment continuing 10 days after surgery (when the intervention commenced is unclear). </p> </li> </ul> </p> <p>Five‐day versus 10‐day LMWH (Comparison 9)</p> <p> <ul id="CD001689-list-0024"> <li> <p><a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a> assessed bemiparin (3500 IU once daily) starting at ≥ eight hours following caesarean for five days versus 10 days. </p> </li> </ul> </p> <p>Weight‐based versus fixed‐dose LMWH (Comparison 10)</p> <p> <ul id="CD001689-list-0025"> <li> <p><a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a> assessed 0.5 mg/kg enoxaparin every 12 hours (dose not capped and rounded to the nearest 5 mg unit) versus 40 mg enoxaparin daily, with the enoxaparin starting between eight and 12 hours after caesarean birth and given as a subcutaneous injection in the abdomen. </p> </li> </ul> </p> <p>LMWH versus LMWH (different types) (Comparison 11)</p> <p> <ul id="CD001689-list-0026"> <li> <p><a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>** evaluated dalteparin (5000 IU) versus enoxaparin (4000 IU) versus tinzaparin (50 IU/kg based on booking weight), all administered once daily, starting from six hours following caesarean section, and continuing for five days. </p> </li> <li> <p>(<a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>)* daily enoxaparin (40 mg) versus daily tinzaparin (4500 units) following caesarean section. </p> </li> </ul> </p> <p>Compression devices versus bed rest (Comparison 12)</p> <p> <ul id="CD001689-list-0027"> <li> <p><a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>: assessed intermittent pneumatic compression during caesarean birth (Aircast Venaflow Calf Cuff—DJO, LLC, Vista, CA, placed on their lower extremities, starting one hour before surgery and continuing ≥ 30 minutes following), versus bed rest beginning one hour before the start of surgery. </p> </li> </ul> </p> <p>Timing of LMWH</p> <p><a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>* evaluated LMWH (0.3 mL nadroparin calcium) 12 hours before versus 12 hours after elective caesarean birth. </p> </section> </section> <section id="CD001689-sec-0072"> <h6 class="title">Postnatal prophylaxis</h6> <p>LMWH versus no treatment or placebo (Comparison 13)</p> <p> <ul id="CD001689-list-0028"> <li> <p><a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> assessed daily prophylactic dalteparin (5000 IU subcutaneous injections starting approximately 36 hours following delivery of the placenta, continued for three weeks), versus placebo. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> assessed the same intervention as <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>, however the dalteparin was administered for longer, following delivery of the placenta (for 10 days), and LMWH was compared with no treatment. </p> </li> </ul> </p> <p>*Trial contributed no data for analysis.</p> <p>**Trial included more than two arms.</p> <p>For further details see <a href="./references#CD001689-sec-0215" title="">Characteristics of included studies</a>. </p> </section> <section id="CD001689-sec-0073"> <h6 class="title">Multi‐arm trials</h6> <p>We combined relevant groups in the multi‐arm trials or included relevant arms as separate comparisons, to create appropriate single pair‐wise comparisons for inclusion in the review analyses, thereby avoiding unit of analysis errors; specifically: </p> <p> <ul id="CD001689-list-0029"> <li> <p><a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>: three arms assessing different types of intrapartum (+ postnatal) LMWH treatment (dalteparin, enoxaparin, tinzaparin) in women undergoing caesarean: we included all three arms in three pair‐wise comparisons as dalteparin versus enoxaparin, dalteparin versus tinzaparin, and enoxaparin versus tinzaparin (Analysis 11). </p> </li> <li> <p><a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>: three arms of intrapartum (+ postnatal) caesarean prophylaxis (LMWH enoxaparin (20 mg daily) versus LMWH enoxaparin (40 mg daily) versus UFH (7500 IU every 12 hours)): we combined the two enoxaparin groups and included this trial in Comparison 8 as LMWH versus UFH. </p> </li> <li> <p><a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>: three arms; two randomised (LMWH dalteparin (5000 IU/daily for seven days post operatively) and UFH (calciparin 2 x 5000 IU daily)), and one not randomised, a control group (a control group received no pharmacological prophylaxis but compression stockings according to guidelines). We included the two randomised groups only, as a pair‐wise comparison of intrapartum (+ postnatal) prophylaxis LMWH versus UFH in Analysis 8. </p> </li> </ul> </p> </section> </section> <section id="CD001689-sec-0074"> <h5 class="title">Outcomes</h5> <p>Primary outcomes: maternal death was reported by three trials (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>) in three separate comparisons. Symptomatic thromboembolic events were reported by 23 trials in 11 of the 13 review comparisons, with between one and four trials in each. Symptomatic PE was reported by 20 trials in 11 comparisons with between one and four trials in each. Symptomatic DVT was reported by 23 trials in 12 comparisons, with between one and five trials in each. </p> <p>Each of our secondary outcomes was reported by at least one/some of the trials, although most in very few comparisons with only one or two trials in each. </p> </section> <section id="CD001689-sec-0075"> <h5 class="title">Sources of trial funding</h5> <p>Thirteen of the 29 included trials reported funding sources: Pharmacia and Upjohn (provided the dalteparin and saline placebo medication, no other intellectual or financial support) (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>); Laboratorios Fcos. ROVI, SA (<a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>); two‐year investigator grant by Pfizer (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>); National Health Service Executive South East Region Research and Development and a donation to the National Perinatal Epidemiology Unit by Rhone‐Poulenc Rorer (<a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>); donation by Rhone‐Poulenc Rorer (<a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>); Leo Laboratories and the South East Thames Regional Health Authority (grant LORS No 77/19) (<a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>); Helsinki University Central Hospital, and Pharmacia and Upjohn (<a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>); Hammond Research Fund, Duke University School of Medicine (<a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>); Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada, drugs supplied by Pharmacia and Upjohn (<a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>); National Institutes of Health Research grant (# NIH 1R34HL107725–01) and Canadian Institutes of Health Research grant (#MOP 106641), Dr. Rodger supported by a Heart and Stroke Foundation Career Investigator Award and a University of Ottawa, Faculty of Medicine Chair in Venous Thrombosis and Thrombophilia, Dr. Kahn supported by a National Research Scholar award from the Fonds de recherche santé Québec (<a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> and <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>); Long Beach Memorial Medical Center Foundation (<a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>); single two‐year investigator grant period 2000–2001 by Pfizer, formerly Pharmacia, grant number 524E‐CVD‐9101‐0001 (Pharmacia was not the sponsor of the study), and a follow‐up study of the trial received a one‐year investigator grant period in 2014 by Pfizer (<a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>). In four of these trials (<a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>) industry was a source of trial support. </p> <p>The remaining 16 trials did not report sources of trial funding.</p> </section> <section id="CD001689-sec-0076"> <h5 class="title">Trial authors’ declarations of interest</h5> <p>In 21 of the included trials authors did not report declarations of interest (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). Two trials reported potential conflicts of interest: <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> declared relevant interests on the part of one author, J. Heller: Consultant/advisory board for BMS/Pfizer; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a> declared relevant interests for one author, A.M. Clement: honoraria for educational activities from Leo Pharma, Sanofi, and Bayer. The authors of these studies reported no other relevant potential conflict of interest. Trial authors of the remaining six included trials declared no conflicts of interest (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>). </p> </section> </section> <section id="CD001689-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We excluded 32 studies. Eight were excluded as they were not randomised controlled trials (<a href="./references#CD001689-bbs2-0031" title="AlalafA , NCT01588171. Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. https://clinicaltrials.gov/ct2/show/NCT01588171 (first received 30 April 2012). AlalafSK , JawadRK , MuhammadPR , AliMS , Al TawilNG . Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. BMC Pregnancy &amp; Childbirth2015;15:72. ">Alalaf 2015</a>; <a href="./references#CD001689-bbs2-0033" title="BlombackM , BremmeK , HellgrenM , LindbergH . A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagulation and Fibrinolysis1998;9:343-50. ">Blomback 1998</a>; <a href="./references#CD001689-bbs2-0045" title="KuttehWH , ErmelLD . A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. American Journal of Reproductive Immunology1996;35:402-7. ">Kutteh 1996a</a>; <a href="./references#CD001689-bbs2-0046" title="KuttehWH . Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology1996;174(5):1584-9. ">Kutteh 1996b</a>; <a href="./references#CD001689-bbs2-0050" title="NobleLS , KuttehWS , LasheyN , FranklinRD , HerradaJ . Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertility and Sterility2005;83(3):684-90. ">Noble 2005</a>; <a href="./references#CD001689-bbs2-0051" title="PyregovA , ShifmanE , ShestakovaO , PuchkoT , BaranovI . Influence of enoxaparine on serum endotoxin concentration in puerpera after abdominal delivery. British Journal of Anaesthesia2012;108:ii212-3. ">Pyregov 2012</a>; <a href="./references#CD001689-bbs2-0053" title="RatiuA , MotocA , PascutD , CrisanDC , AncaT , PascutM . Compression and walking compared with bed rest in the treatment of proximal deep venous thrombosis during pregnancy. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi2009;113(3):795-8. ">Ratiu 2009</a>; <a href="./references#CD001689-bbs2-0056" title="SamanthaP , BarillariG , VenturelliU , TurelloM . Thromboprophylaxis with two different dosages of lmwh (calcic nadroparin) in pregnant women with thrombophilia: a single center experience. Journal of Thrombosis and Haemostasis2013;11:96-7. ">Samantha 2013</a>) (some of these studies were also not eligible based on their study population). <a href="./references#CD001689-bbs2-0030" title="AinaA , NCT00356434. Study of patient compliance and comfort using sequential compression devices and foot pumps for DVT prevention. https://clinicaltrials.gov/ct2/show/results/NCT00356434 (first received 26 July 2006). ">Aina 2006</a> was excluded as it was a protocol reporting a terminated trial. </p> <p>Eighteen studies were excluded as their primary focus was prevention of recurrent miscarriage (<a href="./references#CD001689-bbs2-0032" title="BadawyAM , KhiaryM , SherifLS , HassanM , RagabA , AbdelallI . Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. Journal of Obstetrics and Gynaecology2008;28(3):280-4. ">Badawy 2008</a>; <a href="./references#CD001689-bbs2-0034" title="BrennerB , BarJ , EllisM , YaromI , YohaiD , SamueloffA , et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the live-enox study. Fertility and Sterility2005;84(3):770-3. BrennerB , HoffmanR , CarpH , DulitskyM , SamueloffA , YohaiD , et al. Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study [abstract]. Blood2003;102(11):16a. BrennerB , HoffmanR , CarpH , DulitskyM , SamueloffA , YohalD , et al. Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study [abstract]. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):OC084. BrennerB , HoffmanR , CarpH , DulitskyM , YounisJ , LIVE-ENOX investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. Journal of Thrombosis and Haemostasis2005;3:227-9. BrennerB , for the LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss. The LIVE-ENOX study [abstract]. Blood2002;100(11 Pt 1):702a. ">Brenner 2005</a>; <a href="./references#CD001689-bbs2-0036" title="DendrinosS , KalogirouI , MakrakisE , TheodoridisT , MahmoundEA , Christopoulou-CokkinouV , et al. Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss. Clinical and Experimental Obstetrics and Gynecology2007;34(3):143-5. ">Dendrinos 2007</a>; <a href="./references#CD001689-bbs2-0035" title="deJongPG , QuenbyS , BloemenkampKW , Braams-LismanBA , deBruinJP , CoomarasamyA , et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. Trials2015;16(1):208. ">de Jong 2015</a>; <a href="./references#CD001689-bbs2-0037" title="FarquharsonRG , QuenbyS , GreavesM . Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and Gynecology2002;100(3):408-13. ">Farquharson 2002</a>; <a href="./references#CD001689-bbs2-0038" title="ChistoliniA , TorelliF , GiancottiA , PignoloniP , MutoB , CosimoC , et al. Recurrent fetal loss: prospective evaluation of the efficacy of three different thromboprophylaxis regimens: aspirin versus low molecular weight heparin versus low molecular weight heparin plus aspirin [abstract]. Hematology Journal2006;91(Suppl 1):146. GiancottiA , TorreRL , SpagnuoloA , D'AmbrosioV , CerekjaA , PiazzeJ , et al. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. Journal of Maternal-Fetal and Neonatal Medicine2012;25(7):1191-4. ">Giancotti 2012</a>; <a href="./references#CD001689-bbs2-0041" title="GuvenD , BakayK , KocakI , OzdemirA . Effectiveness of bemiparin sodium for preventing pregnancy loss in patients with MTHFR C677T mutation and habitual abortus. Open Journal of Obstetrics and Gynecology2014;4:930-4. ">Guven 2014</a>; <a href="./references#CD001689-bbs2-0044" title="KaminG , RogenhoferN , Pildner v Steinberg S, NeuhofferA , SeegerS , et al. Therapy with dalteparin for habitual abortion - presentation of the ETHiG II-Studie [Therapie mit Dalteparin bei habitueller Abortneigung - Vorstellung der ETHiG II-Studie]. Geburtshilfe und Frauenheilkunde2008;68:S51. RogenhoferN , MarkoffA , WagnerA , Klein H-G, PetroffD , SchleussnerE , et al. Lessons from the EThIGII trial: Proper putative benefit assessment of low-molecular-weight heparin treatment in M2/ANXA5 haplotype carriers. Clinical and Applied Thrombosis/Hemostasis2017;23(1):27-33. SchleussnerE , BohlmannM , KaminG , RogenhoferN , SeegerS , TothB . Low molecular weight heparin for the prevention of habitual abortion - introduction of the multicentre study EThIG2 and discussion of the current data [Niedermolekulares heparin zur pravention habitueller aborte - vorstellung der multizentrischen EThIG2-studie und diskussion der aktuellen datenlage]. Archives of Gynecology and Obstetrics2012;286(Suppl 1):S220. SchleussnerE , KaminG , SeeligerG , RogenhoferN , TothB . Low-molecular-weight heparin in recurrent pregnancy loss-Results of the ETHIG II study. Thrombosis Research2013;131(Suppl 1):S73. ">Kamin 2008</a>; <a href="./references#CD001689-bbs2-0043" title="KaandorpSP , GoddijnM , van derPostJA , HuttenBA , VerhoeveHR , HamulyákK , et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. New England Journal of Medicine2010;362(17):1586-96. MiddeldorpS . Aspirin and/or low molecular weight heparin for women with unexplained recurrent miscarriage and/or intra-uterine fetal death. Netherlands Trial Register (http://www.trialregister.nl) (first received 1 November 2005). ">Kaandorp 2010</a>; <a href="./references#CD001689-bbs2-0047" title="LangerE , FiedlerA , SchleusnerE , SchlembachD . Placental volume in women under treatment with recurrent miscarriages. Ultraschall in der Medizin, Supplement2013;34(Suppl 1):WS_SL6_05. ">Langer 2013</a>; <a href="./references#CD001689-bbs2-0048" title="LaskinCA , NCT00564174. A randomized controlled trial comparing low molecular weight heparin and aspirin to aspirin alone in women with unexplained recurrent pregnancy loss. https://clinicaltrials.gov/ct2/show/NCT00564174 (first received 27 November 2007). LaskinCA , SpitzerKA , ClarkCA , CrowtherMR , GinsbergJS , HawkerGA , et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. Journal of Rheumatology2009;36(2):279-87. ">Laskin 2007</a>; <a href="./references#CD001689-bbs2-0052" title="CohenH . Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome. Annales de Medicine Interne1996;147 Suppl 1:44. RaiR , CohenH , DaveM , ReganL . Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ1997;314:253-7. ">Rai 1997</a>; <a href="./references#CD001689-bbs2-0055" title="RodgerM , NCT03100123. A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin versus low-molecular-weight heparin (lmwh) and aspirin in women with antiphospholipid syndrome and pregnancy loss. https://clinicaltrials.gov/ct2/show/NCT03100123 (first received 4 April 2017). ">Rodger 2017</a>;<a href="./references#CD001689-bbs2-0057" title="SchleussnerE , KaminG , SeligerG , RogenhoferN , EbnerS , TothB , et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Annals of Internal Medicine2015;162(9):601-9. ">Schleussner 2015</a>; <a href="./references#CD001689-bbs2-0058" title="StephensonMD , BallemPJ , TsangP , PurkissS , EnsworthS , HoulihanE , et al. Treatment of antiphospholipid antibody syndrome (aps) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of Obstetrics and Gynaecology Canada2004;26(8):729-34. ">Stephenson 2004</a>; <a href="./references#CD001689-bbs2-0059" title="ThalerI , BrennerB . Efficacy of enoxaparin for improving pregnancy outcomes and uteroplacental blood flow in women with thrombophilia and recurrent pregnancy loss [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S7. ">Thaler 2004</a>; <a href="./references#CD001689-bbs2-0060" title="TulppalaM , MarttunenM , Soderstrom-AnttilaV , FoudilaT , AilusK , PalosuoT , et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect of prostacyclin and thromboxane A2 production. Human Reproduction1997;12(7):1567-72. ">Tulppala 1997</a>; <a href="./references#CD001689-bbs2-0061" title="VisserJ , UlanderV , BloemenkampK , KaajaR . A randomised controlled multicenter study: the effect of enoxaparin and/or aspirin on prevention of recurrent miscarriage in women with or without thrombophilia, HABENOX-study. International Journal of Gynecology and Obstetrics2009;107(Suppl 2):S371. VisserJ , UlanderVM , HelmerhorstFM , LampinenK , Morin-PapunenL , BloemenkampKW , et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia - HABENOX*: a randomised multicentre trial. Thrombosis and Haemostasis2011;105(2):295-301. ">Visser 2011</a>). Two trials were excluded as they assessed the secondary prevention of placental vascular complications in women with severe pre‐eclampsia or placental abruption and specifically excluded women at increased risk of VTE (<a href="./references#CD001689-bbs2-0039" title="GrisJC , ChauleurC , FaillieJL , BaerG , MaresP , Fabbro-PerayP , et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae: the pilot randomised controlled NOH-AP trial. Thrombosis and Haemostasis2010;104(4):771-9. ">Gris 2010</a>; <a href="./references#CD001689-bbs2-0040" title="GrisJC , ChauleurC , MaresP , NouvellonE , MercierE , BouvierS , et al. Enoxaparin for the secondary prevention of placental complications in women with previous severe pre-eclampsia: the pilot randomised controlled NOH-PE study. Journal of Thrombosis and Haemostasis : JTH2011;9(Suppl 2):753. GrisJC , ChauleurC , MolinariN , MaresP , Fabbro-PerayP , QuereI , et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: the pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis2011;106(6):1053-61. ">Gris 2011</a>). Three trials were excluded as they did not include pregnant women at increased risk of VTE (<a href="./references#CD001689-bbs2-0042" title="HarenbergJ , SchneiderD , HeilmannL , WolfH . Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis1993;23:314-20. ">Harenberg 1993</a>; <a href="./references#CD001689-bbs2-0049" title="MilicD , ZivicS , BogdanovicD , JovanovicM . Compression stockings in the prevention of venous disorders in pregnancy. Phlebology2018;33(10):709. ">Milic 2018</a>; <a href="./references#CD001689-bbs2-0054" title="ReyE , GarneauP , DavidM , GauthierR , LeducL , MichonN , et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis2009;7(1):58-64. ReyE . Dalteparin in prevention of recurrence of severe obstetrical complications in women without thrombophilia. Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S46. ">Rey 2009</a>). </p> <p>For further details, see <a href="./references#CD001689-sec-0216" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD001689-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p>For most of the trials a number of the 'Risk of bias' items were judged 'unclear' due to insufficient methodological detail. Overall, the trials were judged at moderate to high risk of bias. See <a href="#CD001689-fig-0002">Figure 2</a> and <a href="#CD001689-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001689-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001689-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001689-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001689-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001689-sec-0079"> <h4 class="title">Allocation</h4> <p>Generation of the randomisation sequence was considered adequate in 12 trials (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>) and unclear in 17 trials (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). Adequate methods of sequence generation included use of a random number table (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>); use of a central telephone randomisation service (<a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>); and use of a computer‐generated list (<a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>). </p> <p>Methods of allocation concealment were judged as adequate in 10 trials, and included use of pre‐prepared treatment packs dispensed by hospital pharmacy departments (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>), randomisation performed by an independent centre or study coordinator with randomisation codes concealed from the investigators (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>), and sealed opaque envelopes (<a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>). For the remaining 19 studies, the risk of selection bias due to inadequate concealment of allocation was judged to be unclear (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). </p> </section> <section id="CD001689-sec-0080"> <h4 class="title">Blinding</h4> <p>Twenty‐two of the 29 trials were assessed to be at high risk of performance bias, as they did not report adequate attempts to blind participants and study personnel, and adequate blinding was considered unfeasible due to the type of interventions assessed (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). Four trials reported adequate methods used to blind women and study personnel, and were judged at low risk of performance bias (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>). Performance bias was judged unclear for the remaining three trials as while blinding of women and clinicians may have been feasible, there was insufficient information provided (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a> ). </p> <p>Few trials reported any information relating to blinding of outcome assessment, and 22 of the trials were assessed unclear risk of detection bias due to inadequate information provided (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). One trial (<a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>) was judged high risk of detection bias as the authors reported that outcome assessment was not blinded. Six trials were judged at low risk of detection bias as they reported that outcome assessment was blinded (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>). </p> <p>Therefore, only four of the trials reported adequate blinding of women as well as study personnel and outcome assessors (all with the use of a placebo control), and were judged at low risk of performance and detection bias (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>). </p> </section> <section id="CD001689-sec-0081"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty of the 29 trials were judged at a low risk of attrition bias, with very few or no losses to follow‐up or exclusions post‐randomisation reported (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). While two of these studies appeared to have no losses to follow‐up (<a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>), they both reported very little methodological detail. </p> <p>The remaining nine trials were assessed at unclear risk of attrition bias (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>). Of these, six did not specify whether any losses or exclusions occurred (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>). In the <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a> trial, the number of exclusions varied between the tables in the original paper, but it was possible from the text to establish the outcomes for all randomised women. In <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>, 22 of 120 (18%) women were lost to follow‐up; however, data were available for some outcomes. As a result, all women were accounted for in some analyses, but not for the main study outcome (bone mass of the proximal femur), and denominators were not always clear. The <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> trial was assessed at unclear risk of attrition bias despite the authors reporting that "A total of 44 patients enrolled and completed the study", as this was in a conference abstract, the only report for this study. </p> </section> <section id="CD001689-sec-0082"> <h4 class="title">Selective reporting</h4> <p>We judged all except one trial (<a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>) at unclear risk of selective reporting bias. In most cases, the reason for our assessment of unclear was the absence of a trial protocol. However, for <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>, the reason was multiple trial registrations (including on a website), and <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> was assessed as unclear risk due to limited detail provided in the available study protocol. We assessed <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> to be at unclear risk of selective reporting due to limited details in the trial registration available, no full protocol available, and results for clinical outcomes reported incompletely in text. </p> <p><a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>, was judged to be at a high risk of reporting bias, as for a number of clinical outcomes, the data were incompletely reported; for example, groups quote: "showed no differences in the blood loss...and thrombocytopenia or osteopenia". </p> </section> <section id="CD001689-sec-0083"> <h4 class="title">Other potential sources of bias</h4> <p>Thirteen of the trials were judged at a low risk of other potential bias, with no other obvious sources of bias identified (<a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>). </p> <p>The remaining 16 trials were judged at an unclear risk of other potential bias, largely due to a lack of methodological detail provided in the trial reports (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>; <a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>). </p> </section> </section> <section id="CD001689-sec-0084"> <h3 class="title" id="CD001689-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD001689-tbl-0001"><b>Summary of findings 1</b> Antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment/placebo</a>; <a href="./full#CD001689-tbl-0002"><b>Summary of findings 2</b> Antenatal (± postnatal) prophylaxis: LMWH versus UFH</a>; <a href="./full#CD001689-tbl-0003"><b>Summary of findings 3</b> Peripartum/postnatal prophylaxis: UFH versus no treatment</a>; <a href="./full#CD001689-tbl-0004"><b>Summary of findings 4</b> Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment/placebo</a>; <a href="./full#CD001689-tbl-0005"><b>Summary of findings 5</b> Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</a>; <a href="./full#CD001689-tbl-0006"><b>Summary of findings 6</b> Postnatal prophylaxis: LMWH versus no treatment/placebo</a> </p> <section id="CD001689-sec-0085"> <h4 class="title">Comparison 1: Antenatal (<i>±postnatal)</i> prophylaxis: heparin (LMWH or UFH) versus no treatment or placebo </h4> <p>Five trials (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>) involving 519 women were included. See <a href="./full#CD001689-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD001689-sec-0086"> <h5 class="title">Primary outcomes</h5> <p>No trial reported on maternal death.</p> <p>The effects of heparin (LMWH or UFH) versus no treatment or placebo on symptomatic thromboembolic events (risk ratio (RR) 0.39; 95% confidence interval (CI) 0.08 to 1.98; 4 trials, 476 women; <a href="./references#CD001689-fig-0004" title="">Analysis 1.1</a>), symptomatic PE (RR 0.33; 95% CI 0.02 to 7.14; 3 trials, 187 women; <a href="./references#CD001689-fig-0005" title="">Analysis 1.2</a>) and symptomatic DVT (RR 0.33; 95% CI 0.04 to 3.10; 4 trials, 227 women; <a href="./references#CD001689-fig-0006" title="">Analysis 1.3</a>) were very uncertain ‐ all very low‐certainty evidence. </p> </section> <section id="CD001689-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0088"> <h6 class="title">Blood transfusion</h6> <p>No blood transfusions were reported (1 trial, 16 women; <a href="./references#CD001689-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD001689-sec-0089"> <h6 class="title">Bleeding episodes</h6> <p>Bleeding episodes were variably reported across four trials (<a href="./references#CD001689-fig-0008" title="">Analysis 1.5</a>). Effects of LMWH versus no treatment or placebo were very uncertain for placental abruption (RR 1.00; 95% CI 0.31 to 3.20; 3 trials, 463 women), peripartum haemorrhage (RR 0.65; 95% CI 0.24 to 1.79; 1 trial, 289 women); non‐major/minor bleeding (a possible increase with LMWH was observed) (RR 2.12; 95% CI 1.15 to 3.93; 1 trial, 284 women); and major bleeding (RR 1.48; 95% CI 0.25 to 8.72; 1 trial, 284 women). Effects of UFH versus no treatment or placebo were very uncertain for antenatal vaginal bleeding (RR 1.00; 95% CI 0.16 to 6.42; 1 trial, 40 women) and postpartum haemorrhage (RR 3.00; 95% CI 0.13 to 69.52; 1 trial, 40 women). </p> </section> <section id="CD001689-sec-0090"> <h6 class="title">Serious wound complications</h6> <p>There were no serious wound complications (1 trial, 16 women; <a href="./references#CD001689-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD001689-sec-0091"> <h6 class="title">Adverse effects sufficient to stop treatment</h6> <p>The effect of heparin versus no treatment or placebo on adverse effects sufficient to stop treatment was very uncertain (RR 0.49; 95% CI 0.05 to 5.31; 1 trial, 139 women; very low‐certainty evidence; <a href="./references#CD001689-fig-0010" title="">Analysis 1.7</a>). There were 3 events: heparin (LMWH) 1 event (bleeding from placental praevia); no treatment 2 events (both stomach complaints). </p> </section> <section id="CD001689-sec-0092"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>Adverse effects not sufficient to stop treatment were variably reported across four trials. The effects of heparin versus no treatment or placebo were very uncertain for skin/allergic reactions (a possible increase with heparin was observed) (RR 5.11; 95% CI 2.00 to 13.08; 4 trials, 476 women), raised liver enzymes (a possible increase with heparin was observed) (RR 22.53; 95% CI 1.34 to 378.78; 1 trial, 289 women), haematoma (RR 3.98; 95% CI 0.46 to 34.23; 2 trials, 171 women), superficial thrombophlebitis (RR 0.33; 95% CI 0.01 to 7.93; 1 trial, 139 women) and 'other' adverse effects (including transient ischaemic attack, severe allergic reaction) (RR 0.98; 95% CI 0.06 to 15.51; 1 trial, 289 women) (<a href="./references#CD001689-fig-0011" title="">Analysis 1.8</a>). </p> <p><a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a> reported that "Few women reported side effects"; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a> reported “Minor side‐effects from heparin prophylaxis included bruising at the injection site (reduced by good injection technique), epistaxis and the inconvenience of giving twice‐daily injections"; and <a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> reported "70 women in the LMWH‐aspirin group had to convert to LMWH prescription". </p> </section> <section id="CD001689-sec-0093"> <h6 class="title">Symptomatic osteoporosis</h6> <p>The effect of heparin versus no treatment or placebo on thrombocytopenia was very uncertain (RR 3.00; 95% CI 0.13 to 69.52; 4 trials, 479 women; <a href="./references#CD001689-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD001689-sec-0094"> <h6 class="title">Fetal loss</h6> <p>The effect of heparin versus no treatment or placebo on fetal loss was very uncertain (<a href="./references#CD001689-fig-0013" title="">Analysis 1.10</a>): where gestation was unclear (RR 1.16; 95% CI 0.54 to 2.51; 2 trials, 329 women), at less than 20 weeks' gestation (RR 2.18; 95% CI 0.50 to 9.41; 2 trials, 171 women), and at least 20 weeks' gestation (RR 0.33; 95% CI 0.04 to 3.12; 2 trials, 166 women). </p> </section> <section id="CD001689-sec-0095"> <h6 class="title">Thrombocytopenia</h6> <p>The effect of heparin versus no treatment or placebo on thrombocytopenia was very uncertain (RR 3.00; 95% CI 0.14 to 64.26; 5 trials, 511 women; <a href="./references#CD001689-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD001689-sec-0096"> <h6 class="title">Fetal anomalies</h6> <p>The effect of heparin versus no treatment or placebo on fetal anomalies was very uncertain (RR 2.94; 95% CI 0.61 to 14.32; 1 trial, 289 women; <a href="./references#CD001689-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD001689-sec-0097"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events.</p> </section> </section> </section> <section id="CD001689-sec-0098"> <h4 class="title">Comparison 2: Antenatal (<i>±postnatal)</i> prophylaxis: LMWH versus UFH </h4> <p>Four trials (<a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>) involving 404 women were included. See <a href="./full#CD001689-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD001689-sec-0099"> <h5 class="title">Primary outcomes</h5> <p>No trial reported on maternal death.</p> <p>The effect of LMWH versus UFH on symptomatic thromboembolic events was very uncertain (RR 0.47; 95% CI 0.09 to 2.49; 4 trials, 404 women; very low‐certainty evidence; <a href="./references#CD001689-fig-0016" title="">Analysis 2.1</a>). There were no cases of symptomatic PE (3 trials, 287 women; <a href="./references#CD001689-fig-0017" title="">Analysis 2.2</a>), or symptomatic DVT (3 trials, 287 women; <a href="./references#CD001689-fig-0018" title="">Analysis 2.3</a>) in the LWMH or UFH groups. </p> </section> <section id="CD001689-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0101"> <h6 class="title">Blood transfusion</h6> <p>The effect of LMWH versus UFH on blood transfusions was very uncertain (RR 0.22; 95% CI 0.01 to 4.47; 1 trial, 105 women; <a href="./references#CD001689-fig-0019" title="">Analysis 2.4</a>). </p> </section> <section id="CD001689-sec-0102"> <h6 class="title">Bleeding episodes</h6> <p>Bleeding episodes were variably reported across three trials (<a href="./references#CD001689-fig-0020" title="">Analysis 2.5</a>). Effects of LMWH versus no treatment or placebo were very uncertain for bruises greater than 2.5 cm (a possible reduction with LMWH was observed) (RR 0.18; 95% CI 0.09 to 0.36; 1 trial, 121 women), bleeding at birth (RR 3.80; 95% CI 0.44 to 32.99; 1 trial, 117 women), and 'bleeding complications' (a possible reduction with LMWH was observed) (RR 0.28; 95% CI 0.15 to 0.53; 1 trial, 105 women). </p> </section> <section id="CD001689-sec-0103"> <h6 class="title">Serious wound complications</h6> <p>No trial reported this outcome.</p> </section> <section id="CD001689-sec-0104"> <h6 class="title">Adverse effects sufficient to stop treatment</h6> <p>LMWH compared with UFH may reduce adverse effects sufficient to stop treatment but this evidence was very uncertain (RR 0.07; 95% CI 0.01 to 0.54; 2 trials, 226 women; very low‐certainty evidence; <a href="./references#CD001689-fig-0021" title="">Analysis 2.6</a>). There were 13 events in UFH group: 1 stopped due to an allergic reaction, 1 due to mild anaemia with no confirmed bleeding and 11 due to excess bruising/allergic rashes (these 11 stopped switched to LMWH (dalteparin) and the adverse effects resolved). </p> </section> <section id="CD001689-sec-0105"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>The effect of LMWH versus UFH on adverse effects (injection burning) not sufficient to stop treatment was very uncertain (RR 0.79; 95% CI 0.53 to 1.18; 1 trial, 121 women; <a href="./references#CD001689-fig-0022" title="">Analysis 2.7</a>). </p> </section> <section id="CD001689-sec-0106"> <h6 class="title">Symptomatic osteoporosis</h6> <p>The effect of LMWH versus UFH on symptomatic osteoporosis was very uncertain (RR 0.43; 95% CI 0.06 to 2.98; 2 trials, 188 women; <a href="./references#CD001689-fig-0023" title="">Analysis 2.8</a>). </p> </section> <section id="CD001689-sec-0107"> <h6 class="title">Fetal loss</h6> <p>The effect of LMWH versus UFH on fetal loss was very uncertain (<a href="./references#CD001689-fig-0024" title="">Analysis 2.9</a>): where gestation was unclear (RR 0.61; 95% CI 0.21 to 1.77; 2 trials, 222 women) and at less than 20 weeks' gestation (RR 0.38; 95% CI 0.14 to 1.00; 1 trial, 121 women). </p> </section> <section id="CD001689-sec-0108"> <h6 class="title">Thrombocytopenia</h6> <p>The effect of LMWH versus UFH on thrombocytopenia was very uncertain (RR 0.18; CI 0.01 to 3.64; 95%; 3 trials, 287 women; <a href="./references#CD001689-fig-0025" title="">Analysis 2.10</a>). </p> </section> <section id="CD001689-sec-0109"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; fetal anomalies.</p> </section> </section> </section> <section id="CD001689-sec-0110"> <h4 class="title">Comparison 3: Antenatal (<i>±postnatal)</i> prophylaxis: adjusted‐ versus fixed‐dose LMWH </h4> <p>One trial (<a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>) involving 144 women was included. </p> <section id="CD001689-sec-0111"> <h5 class="title">Primary outcomes</h5> <p>A single trial did not report on maternal death, and reported no events in either the adjusted‐dose or fixed‐dose groups for symptomatic thromboembolic events (<a href="./references#CD001689-fig-0026" title="">Analysis 3.1</a>), symptomatic PE (<a href="./references#CD001689-fig-0027" title="">Analysis 3.2</a>) or symptomatic DVT (<a href="./references#CD001689-fig-0028" title="">Analysis 3.3</a>); 140 women. </p> </section> <section id="CD001689-sec-0112"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0113"> <h6 class="title">Asymptomatic thromboembolic events</h6> <p>There were no asymptomatic thromboembolic events in the adjusted‐dose or fixed‐dose LMWH groups (1 trial, 140 women; <a href="./references#CD001689-fig-0029" title="">Analysis 3.4</a>). </p> </section> <section id="CD001689-sec-0114"> <h6 class="title">Bleeding episodes</h6> <p>The trial reported variations of bleeding episodes (<a href="./references#CD001689-fig-0030" title="">Analysis 3.5</a>); the effects of adjusted‐dose versus fixed‐dose LMWH on placental abruption (RR 0.22; 95% CI 0.03 to 1.95; 1 trial, 140 women), postpartum haemorrhage (RR 0.08; 95% CI 0.00 to 1.44; 1 trial, 140 women) and 'bleeding side effects' (no events) were very uncertain. </p> </section> <section id="CD001689-sec-0115"> <h6 class="title">Adverse effects sufficient to stop treatment</h6> <p>The effect of adjusted‐dose versus fixed‐dose LMWH on adverse effects sufficient to stop treatment (skin allergy) was very uncertain (RR 0.35, 95% CI 0.01 to 8.50; 1 trial, 144 women; <a href="./references#CD001689-fig-0031" title="">Analysis 3.6</a>). </p> </section> <section id="CD001689-sec-0116"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>The effect of adjusted‐dose versus fixed‐dose LMWH on adverse effects not sufficient to stop treatment (skin allergy) was very uncertain (RR 0.30, 95% CI 0.01 to 7.19; 1 trial, 140 women; <a href="./references#CD001689-fig-0032" title="">Analysis 3.7</a>). </p> </section> <section id="CD001689-sec-0117"> <h6 class="title">Fetal loss</h6> <p>The effects of adjusted‐dose versus fixed‐dose LMWH on fetal loss at less than 20 weeks' gestation (RR 4.47; 95% CI 0.22 to 91.38; 1 trial, 140 women), and at least 20 weeks' gestation (RR 2.68; 95% CI 0.11 to 64.68; 1 trial, 140 women) were very uncertain (<a href="./references#CD001689-fig-0033" title="">Analysis 3.8</a>). </p> </section> <section id="CD001689-sec-0118"> <h6 class="title">Thrombocytopenia</h6> <p>There were no cases of thrombocytopenia in the adjusted‐dose or fixed‐dose LMWH groups (1 trial, 140 women; <a href="./references#CD001689-fig-0034" title="">Analysis 3.9</a>). </p> </section> <section id="CD001689-sec-0119"> <h6 class="title">Secondary outcomes not reported</h6> <p>Blood transfusion; serious wound complications; symptomatic osteoporosis; fetal anomalies.</p> </section> </section> </section> <section id="CD001689-sec-0120"> <h4 class="title">Comparison 4: Antenatal (<i>±postnatal)</i> prophylaxis: compression stockings versus none </h4> <p>One trial (<a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a>) involving 44 women was included. </p> <section id="CD001689-sec-0121"> <h5 class="title">Primary outcomes</h5> <p>The trial did not report on maternal death, symptomatic thromboembolic events or symptomatic VTE. There were no cases of symptomatic DVT in the compression stockings or no compression stockings groups (1 trial, 44 women <a href="./references#CD001689-fig-0035" title="">Analysis 4.1</a>). </p> </section> <section id="CD001689-sec-0122"> <h5 class="title">Secondary outcomes</h5> <p>No cases of adverse effects sufficient to stop treatment were reported (1 trial, 44 women; <a href="./references#CD001689-fig-0036" title="">Analysis 4.2</a>). </p> <section id="CD001689-sec-0123"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; blood transfusion; bleeding episodes; serious wound complications; adverse effects sufficient to stop treatment; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0124"> <h4 class="title">Comparison 5: Peripartum prophylaxis: UFH versus no treatment</h4> <p>One trial (<a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>) involving 210 women was included. See <a href="./full#CD001689-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD001689-sec-0125"> <h5 class="title">Primary outcomes</h5> <p>The included trial (<a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a>) did not report on maternal death. The effects of UFH versus no heparin on symptomatic thromboembolic events (RR 0.16; 95% CI 0.02 to 1.36; 1 trial, 210 women; <a href="./references#CD001689-fig-0037" title="">Analysis 5.1</a>), symptomatic PE (RR 0.16; 95% CI 0.01 to 3.34; 1 trial, 210 women; <a href="./references#CD001689-fig-0038" title="">Analysis 5.2</a>), and symptomatic DVT (RR 0.27; 95% CI 0.03 to 2.55; 1 trial; 210 women; <a href="./references#CD001689-fig-0039" title="">Analysis 5.3</a>) were very uncertain ‐ all very low‐certainty evidence. </p> </section> <section id="CD001689-sec-0126"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0127"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; blood transfusion; bleeding episodes; serious wound complications; adverse effects sufficient to stop treatment; adverse effects not sufficient to stop treatment; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0128"> <h4 class="title">Comparison 6: Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment or placebo </h4> <p>Five trials (<a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>) involving 1147 women were included. See <a href="./full#CD001689-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD001689-sec-0129"> <h5 class="title">Primary outcomes</h5> <p>There were no cases of maternal death (1 trial, 300 women; <a href="./references#CD001689-fig-0040" title="">Analysis 6.1</a>). The effects of heparin versus no treatment or placebo on symptomatic thromboembolic events (RR 1.30; 95% CI 0.39 to 4.27; 4 trials, 840 women; <a href="./references#CD001689-fig-0041" title="">Analysis 6.2</a>), symptomatic PE (RR 1.10; 95% CI 0.25 to 4.87; 4 trials, 840 women; <a href="./references#CD001689-fig-0042" title="">Analysis 6.3</a>), and symptomatic DVT (RR 1.30; 95% CI 0.24 to 6.94; 5 trials, 1140 women; <a href="./references#CD001689-fig-0043" title="">Analysis 6.4</a>) were very uncertain ‐ all very low‐certainty evidence. </p> </section> <section id="CD001689-sec-0130"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0131"> <h6 class="title">Blood transfusion</h6> <p>The effect of heparin versus no treatment or placebo on blood transfusion was very uncertain (RR 0.24; 95% CI 0.03 to 2.13; 3 trials, 266 women; <a href="./references#CD001689-fig-0044" title="">Analysis 6.5</a>). </p> </section> <section id="CD001689-sec-0132"> <h6 class="title">Bleeding episodes</h6> <p>Bleeding episodes were variously reported across four trials. There were no cases of major bleeding (1 trial, 76 women) or major bruising (1 trial, 76 women). The effects of heparin versus no treatment or placebo were very uncertain for: bleeding complications (a possible increase with heparin was observed) (RR 5.03; 95% CI 2.49 to 10.18; 2 trials, 714 women), bleeding/bruising at discharge (RR 6.17; 95% CI 0.76 to 49.96; 1 trial, 140 women), blood loss less than 500 mL (RR 1.50; 95% CI 0.63 to 3.59; 1 trial, 50 women), blood loss 500 mL to 1000 mL (RR 0.81; 95% CI 0.50 to 1.31; 1 trial, 50 women), blood loss 1000 mL to 1500 mL (RR 0.50; 95% CI 0.05 to 5.17; 1 trial, 50 women), and blood loss 1500 mL to 2000 mL (RR 2.00; 95% CI 0.19 to 20.67; 1 trial, 50 women; <a href="./references#CD001689-fig-0045" title="">Analysis 6.6</a>). </p> </section> <section id="CD001689-sec-0133"> <h6 class="title">Serious wound complications</h6> <p>Serious wound complications were variably reported in three trials; no major wound disruptions were reported in the heparin and no treatment or placebo groups (2 trials, 126 women); the effect of heparin versus no treatment or placebo on wound infection was very uncertain (RR 2.30; 95% CI 0.34 to 15.53; 2 trials, 216 women; <a href="./references#CD001689-fig-0046" title="">Analysis 6.7</a>). </p> </section> <section id="CD001689-sec-0134"> <h6 class="title">Adverse effects sufficient to stop treatment</h6> <p>There were no cases of adverse effects sufficient to stop treatment (1 trial, 140 women; <a href="./references#CD001689-fig-0047" title="">Analysis 6.8</a>). </p> </section> <section id="CD001689-sec-0135"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>There were no cases of adverse effects insufficient to stop treatment (1 trial, 76 women; <a href="./references#CD001689-fig-0048" title="">Analysis 6.9</a>). </p> </section> <section id="CD001689-sec-0136"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0137"> <h4 class="title">Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH</h4> <p>One trial (<a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a>) involving 207 women was included. </p> <section id="CD001689-sec-0138"> <h5 class="title">Primary outcomes</h5> <p>The trial did not report on maternal death, symptomatic thromboembolic events, symptomatic PE or symptomatic DVT. </p> </section> <section id="CD001689-sec-0139"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0140"> <h6 class="title">Asymptomatic thromboembolic events</h6> <p>The effect of HES versus UFH on asymptomatic thromboembolic events was very uncertain (RR 0.76; 95% CI 0.27 to 2.11; 1 trial, 207 women; <a href="./references#CD001689-fig-0049" title="">Analysis 7.1</a>). </p> </section> <section id="CD001689-sec-0141"> <h6 class="title">Blood transfusion</h6> <p>The effect of HES versus UFH on blood transfusions was very uncertain (RR 0.50; 95% CI 0.05 to 5.48; 1 trial, 207 women <a href="./references#CD001689-fig-0050" title="">Analysis 7.2</a>). </p> </section> <section id="CD001689-sec-0142"> <h6 class="title">Bleeding episodes</h6> <p>The effect of HES versus UFH on bleeding episodes was very uncertain (RR 0.40; 95% CI 0.08 to 2.03; 1 trial, 207 women; <a href="./references#CD001689-fig-0051" title="">Analysis 7.3</a>). </p> </section> <section id="CD001689-sec-0143"> <h6 class="title">Wound complications</h6> <p>The effect of HES versus UFH on wound complications was very uncertain (RR 0.67; 95% CI 0.25 to 1.82; 1 trial, 207 women; <a href="./references#CD001689-fig-0052" title="">Analysis 7.4</a>). </p> </section> <section id="CD001689-sec-0144"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; adverse effects sufficient to stop treatment; adverse effects not sufficient to stop treatment; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0145"> <h4 class="title">Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</h4> <p>Three trials (<a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a>) involving 217 women were included. See <a href="./full#CD001689-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD001689-sec-0146"> <h5 class="title">Primary outcomes</h5> <p>No trials reported on maternal death. The effects of LMWH versus UFH on symptomatic thromboembolic events (RR 0.33; 95% CI 0.01 to 7.99; 3 trials, 217 women; <a href="./references#CD001689-fig-0053" title="">Analysis 8.1</a>) and symptomatic DVT (RR 0.33; 95% CI 0.01 to 7.99; 3 trials, 217 women; <a href="./references#CD001689-fig-0055" title="">Analysis 8.3</a>), were very uncertain ‐ both very low‐certainty evidence. There were no cases of symptomatic PE (3 trials, 217 women; <a href="./references#CD001689-fig-0054" title="">Analysis 8.2</a>). </p> </section> <section id="CD001689-sec-0147"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0148"> <h6 class="title">Bleeding episodes</h6> <p>There were no cases of bleeding episodes (variously defined) in the LMWH and UFH groups: 'haemorrhagic event' (1 trial, 17 women), major bleeding (1 trial, 100 women), and post surgical haemorrhage (1 trial, 100 women) (<a href="./references#CD001689-fig-0056" title="">Analysis 8.4</a>). </p> </section> <section id="CD001689-sec-0149"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>There were no adverse effects not sufficient to stop treatment (1 trial, 100 women; <a href="./references#CD001689-fig-0057" title="">Analysis 8.5</a>). </p> </section> <section id="CD001689-sec-0150"> <h6 class="title">Thrombocytopenia</h6> <p>There were no cases of thrombocytopenia (1 trial, 100 women; <a href="./references#CD001689-fig-0058" title="">Analysis 8.6</a>). Another trial (<a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>) reported that "The clinical outcome showed no differences in... the different prophylaxis groups and thrombocytopenia." </p> </section> <section id="CD001689-sec-0151"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; blood transfusions; adverse effects sufficient to stop treatment; symptomatic osteoporosis; fetal loss; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0152"> <h4 class="title">Comparison 9: Peripartum/postnatal prophylaxis (caesarean): five‐day versus 10‐day LMWH </h4> <p>One trial (<a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>) involving 646 women was included. </p> <section id="CD001689-sec-0153"> <h5 class="title">Primary outcomes</h5> <p>There were no maternal deaths (1 trial, 646 women; <a href="./references#CD001689-fig-0059" title="">Analysis 9.1</a>) or cases of symptomatic DVT (1 trial, 646 women; <a href="./references#CD001689-fig-0062" title="">Analysis 9.4</a>) in the five‐day and 10‐day LMWH groups. The effects of five‐day versus 10‐day LMWH on symptomatic thromboembolic events (RR 0.36; 95% CI 0.01 to 8.78; 1 trial, 646 women; <a href="./references#CD001689-fig-0060" title="">Analysis 9.2</a>) and symptomatic PE (RR 0.36; 95% CI 0.01 to 8.78; 1 trial, 646 women; <a href="./references#CD001689-fig-0061" title="">Analysis 9.3</a>) were very uncertain. </p> </section> <section id="CD001689-sec-0154"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0155"> <h6 class="title">Bleeding episodes</h6> <p>There were no bleeding episodes (1 trial, 646 women; <a href="./references#CD001689-fig-0063" title="">Analysis 9.5</a>). </p> </section> <section id="CD001689-sec-0156"> <h6 class="title">Serious wound complications</h6> <p>The effects of five‐day versus 10‐day LMWH on post caesarean infection (RR 1.13; 95% CI 0.63 to 2.05; 1 trial, 646 women) and post caesarean seroma (RR 1.14; 95% CI 0.59 to 2.23; 1 trial. 646 women) were very uncertain (<a href="./references#CD001689-fig-0064" title="">Analysis 9.6</a>). </p> </section> <section id="CD001689-sec-0157"> <h6 class="title">Thrombocytopenia</h6> <p>There were no cases of thrombocytopenia (1 trial, 646 women; <a href="./references#CD001689-fig-0065" title="">Analysis 9.7</a>). </p> </section> <section id="CD001689-sec-0158"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; blood transfusions; adverse effects sufficient to stop treatment; adverse effects not sufficient to stop treatment; symptomatic osteoporosis; fetal losses; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0159"> <h4 class="title">Comparison 10: Peripartum/postnatal prophylaxis (caesarean): weight‐based versus fixed‐dose LMWH </h4> <p>One trial (<a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a>) involving 90 women was included. </p> <section id="CD001689-sec-0160"> <h5 class="title">Primary outcomes</h5> <p>Maternal death was not reported. There were no cases of symptomatic thromboembolic events (1 trial, 84 women; <a href="./references#CD001689-fig-0066" title="">Analysis 10.1</a>), symptomatic PE (1 trial, 84 women; <a href="./references#CD001689-fig-0067" title="">Analysis 10.2</a>) or symptomatic DVT (no events; 1 trial, 84 women; <a href="./references#CD001689-fig-0068" title="">Analysis 10.3</a>) in the weight‐based and fixed‐dose LMWH groups. </p> </section> <section id="CD001689-sec-0161"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0162"> <h6 class="title">Blood transfusion</h6> <p>No blood transfusions were reported (1 trial, 84 women; <a href="./references#CD001689-fig-0069" title="">Analysis 10.4</a>). </p> </section> <section id="CD001689-sec-0163"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p><a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a> reported narratively in text on one "possible case of heparin‐induced skin necrosis" in the weight‐based LMWH group. </p> </section> <section id="CD001689-sec-0164"> <h6 class="title">Serious wound complications</h6> <p>The effects of weight‐based versus fixed‐dose LMWH on wound infection (RR 0.20; 95% CI 0.01 to 4.04; 1 trial, 84 women) and wound haematoma (RR 0.33; 95% CI 0.04 to 3.08; 1 trial, 84 women) were very uncertain (<a href="./references#CD001689-fig-0070" title="">Analysis 10.5</a>). There were no cases of wound dehiscence or reoperation (1 trial, 84 women) (<a href="./references#CD001689-fig-0070" title="">Analysis 10.5</a>). </p> </section> <section id="CD001689-sec-0165"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; bleeding episodes; adverse effects sufficient to stop treatment; adverse effects not sufficient to stop treatment; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0166"> <h4 class="title">Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types) </h4> <p>One trial (<a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>) involving 30 women was included. </p> <section id="CD001689-sec-0167"> <h5 class="title">Primary outcomes</h5> <p>Maternal death was not reported. There were no cases of symptomatic thromboembolic events, symptomatic PE or symptomatic DVT in comparisons of dalteparin versus enoxaparin, dalteparin versus tinzaparin, and enoxaparin versus tinzaparin (1 trial, 20 women in each comparison for each outcome; <a href="./references#CD001689-fig-0071" title="">Analysis 11.1</a>; <a href="./references#CD001689-fig-0072" title="">Analysis 11.2</a>; <a href="./references#CD001689-fig-0073" title="">Analysis 11.3</a>). </p> </section> <section id="CD001689-sec-0168"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0169"> <h6 class="title">Bleeding episodes</h6> <p>There were no bleeding episodes (excessive bruising) in comparisons of dalteparin versus enoxaparin, dalteparin versus tinzaparin, and enoxaparin versus tinzaparin (1 trial, 20 women in each comparison; <a href="./references#CD001689-fig-0074" title="">Analysis 11.4</a>). </p> </section> <section id="CD001689-sec-0170"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>There were no adverse effects (not sufficient to stop treatment (skin reactions)) in comparisons of dalteparin versus enoxaparin, dalteparin versus tinzaparin, and enoxaparin versus tinzaparin (1 trial, 20 women in each comparison; <a href="./references#CD001689-fig-0075" title="">Analysis 11.5</a>). </p> </section> <section id="CD001689-sec-0171"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; blood transfusion; serious wound complications; adverse effects sufficient to stop treatment; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0172"> <h4 class="title">Comparison 12: Peripartum/postnatal prophylaxis (caesarean): compression devices versus bed rest </h4> <p>One trial (<a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a>) involving 50 women was included. </p> <section id="CD001689-sec-0173"> <h5 class="title">Primary outcomes</h5> <p>Maternal death was not reported. There were no cases of symptomatic thromboembolic events (1 trial, 49 women; <a href="./references#CD001689-fig-0076" title="">Analysis 12.1</a>), symptomatic PE (1 trial, 49 women; <a href="./references#CD001689-fig-0077" title="">Analysis 12.2</a>) or symptomatic DVT (1 trial, 49 women; <a href="./references#CD001689-fig-0078" title="">Analysis 12.3</a>) in the compression devices and bed rest groups. </p> </section> <section id="CD001689-sec-0174"> <h5 class="title">Secondary outcomes</h5> <p>No blood transfusions were reported (1 trial, 49 women; <a href="./references#CD001689-fig-0079" title="">Analysis 12.4</a>). </p> <section id="CD001689-sec-0175"> <h6 class="title">Secondary outcomes not reported</h6> <p>Asymptomatic thromboembolic events; bleeding episodes; serious wound complications; adverse effects sufficient to stop treatment; adverse effects not sufficient to stop treatment; symptomatic osteoporosis; fetal loss; thrombocytopenia; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0176"> <h4 class="title">Comparison 13: Postnatal prophylaxis: LMWH versus no treatment or placebo</h4> <p>Two trials (<a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>) involving 62 women, were included. See <a href="./full#CD001689-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD001689-sec-0177"> <h5 class="title">Primary outcomes</h5> <p>There were no cases of maternal death (1 trial, 24 women; <a href="./references#CD001689-fig-0080" title="">Analysis 13.1</a>), symptomatic thromboembolic events (2 trials, 58 women; <a href="./references#CD001689-fig-0081" title="">Analysis 13.2</a>), symptomatic PE (2 trials, 58 women; <a href="./references#CD001689-fig-0082" title="">Analysis 13.3</a>), or symptomatic DVT (2 trials, 58 women; <a href="./references#CD001689-fig-0083" title="">Analysis 13.4</a>) in the LMWH and no treatment or placebo groups. </p> </section> <section id="CD001689-sec-0178"> <h5 class="title">Secondary outcomes</h5> <section id="CD001689-sec-0179"> <h6 class="title">Assymptomatic thromboembolic events</h6> <p>There were no asymptomatic thromboembolic events (2 trials, 58 women; <a href="./references#CD001689-fig-0084" title="">Analysis 13.5</a>). </p> </section> <section id="CD001689-sec-0180"> <h6 class="title">Bleeding episodes</h6> <p>Bleeding episodes were variably reported by the two trials. The effects of LMWH versus no treatment or placebo on major bleeding (RR 3.53; 95% CI 0.15 to 81.11; 2 trials, 59 women), clinically relevant bleeding events (RR 5.88; 95% CI 0.30‐114.28; 1 trial, 35 women), and minor bleeding events (RR 3.53; 95% CI 0.15 to 81.11; 1 trial, 35 women) were very uncertain (<a href="./references#CD001689-fig-0085" title="">Analysis 13.6</a>). </p> </section> <section id="CD001689-sec-0181"> <h6 class="title">Adverse effects not sufficient to stop treatment</h6> <p>The effect of LMWH versus placebo or no treatment on adverse effects not sufficient to stop treatment was very uncertain (RR 3.53; 95% CI 0.15 to 81.11; 2 trials, 59 women; <a href="./references#CD001689-fig-0086" title="">Analysis 13.7</a>). </p> </section> <section id="CD001689-sec-0182"> <h6 class="title">Thrombocytopenia</h6> <p>There were no cases of thrombocytopenia (1 trial, 24 women; <a href="./references#CD001689-fig-0087" title="">Analysis 13.8</a>). </p> </section> <section id="CD001689-sec-0183"> <h6 class="title">Secondary outcomes not reported</h6> <p>Blood transfusion; serious wound complications; adverse effects sufficient to stop treatment; symptomatic osteoporosis; fetal loss; fetal anomalies. </p> </section> </section> </section> <section id="CD001689-sec-0184"> <h4 class="title">Sensitivity analysis</h4> <p>Nine high‐quality trials (judged to be at low risk of both selection bias and attrition bias) (<a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>; <a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a>) were identified for sensitivity analyses. Sensitivity analyses for Comparisons 3 (<a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a>) and 13 (<a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a>) were not replicated below; as trials for inclusion were the same as in the main analyses. </p> </section> <section id="CD001689-sec-0185"> <h4 class="title">Comparison 1: Antental (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment or placebo </h4> <p>For the outcomes symptomatic thromboembolic events (<a href="./references#CD001689-fig-0088" title="">Analysis 14.1</a>) and symptomatic PE (<a href="./references#CD001689-fig-0089" title="">Analysis 14.2</a>), sensitivity analyses included the same trials (and thus results) as the main analyses. In the sensitivity analysis the effect of heparin versus no treatment or placebo on symptomatic DVT was very uncertain (RR 0.33; 95% CI 0.01 to 7.93; 3 trials, 187 women), as in the main analysis. </p> </section> <section id="CD001689-sec-0186"> <h4 class="title">Comparison 2: Antental (± postnatal) prophylaxis: LMWH versus UFH</h4> <p>On sensitivity analysis, there were no symptomatic thromboembolic events, symptomatic PE or DVT reported (1 trial, 105 women) (<a href="./references#CD001689-fig-0091" title="">Analysis 15.1</a>; <a href="./references#CD001689-fig-0092" title="">Analysis 15.2</a>; <a href="./references#CD001689-fig-0093" title="">Analysis 15.3</a>). Unlike the main analysis for symptomatic thromboembolic events (where the effect was very uncertain), the sensitivity analysis included no cases (1 trial, 105 women) (<a href="./references#CD001689-fig-0091" title="">Analysis 15.1</a>). </p> </section> <section id="CD001689-sec-0187"> <h4 class="title">Comparison 6: Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH) versus no treatment or placebo </h4> <p>As in the main analyses, sensitivity analyses suggested the effects of heparin versus no treatment or placebo on symptomatic thromboembolic events and PE were very uncertain (both RR 3.09; 95% CI 0.13 to 74.51; 1 trial, 134 women; <a href="./references#CD001689-fig-0094" title="">Analysis 16.1</a>; <a href="./references#CD001689-fig-0095" title="">Analysis 16.2</a>). Unlike in the main analysis for symptomatic DVT (where the effect was very uncertain), the sensitivity analysis included no cases (1 trial, 134 women) (<a href="./references#CD001689-fig-0096" title="">Analysis 16.3</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001689-sec-0188" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001689-sec-0188"></div> <section id="CD001689-sec-0189"> <h3 class="title" id="CD001689-sec-0189">Summary of main results</h3> <p>In this updated review, we included 29 randomised controlled trials comparing effects of various methods of thromboprophylaxis in women who were pregnant or who had recently given birth and were at increased risk of venous thromboembolism (VTE). The included trials contributed data across 13 comparisons. </p> <p><b>Antenatal (± postnatal) prophylaxis:</b> effects were very uncertain (very low‐certainty evidence, where assessed; or could not be determined due to no events) across all comparisons that reported symptomatic thromboembolic events, symptomatic pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT) and/or adverse effects sufficient to stop treatment (heparin versus no treatment/placebo (maximum of four trials, 476 women); low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) (maximum of 4 trials, 404 women); adjusted‐dose versus fixed‐dose LMWH (maximum of one trial, 144 women); compression stockings versus none (maximum one trial, 44 women). Maternal death was not reported. </p> <p><b>Peripartum/postnatal prophylaxis: <i>for</i> <i>vaginal birth or caesarean birth:</i> </b> effects were very uncertain in the comparison of UFH versus no treatment for symptomatic thromboembolic events, symptomatic PE and symptomatic DVT (one trial, 210 women). Maternal death and adverse effects sufficient to stop treatment were not reported. </p> <p><i><b>For caesarean birth:</b> </i> effects were very uncertain (very low‐certainty evidence where assessed; or could not be determined due to no events) across all comparisons that reported maternal death, symptomatic thromboembolic events, symptomatic PE, symptomatic DVT, adverse effects sufficient to stop treatment (heparin versus no treatment/placebo (maximum of 5 trials, 1140 women); LMWH versus UFH (3 trials, 217 women); five‐day versus 10‐day LMWH (one trial, 646 women); weight‐based versus fixed‐dose LMWH (1 trial, 84 women); comparisons of different types of LMWH (1 trial; 30 women); compression devices versus bed rest (1 trial, 49 women). </p> <p><b>Postnatal prophylaxis:</b> there were no events in the comparison of LMWH versus no treatment/placebo for maternal death, symptomatic thromboembolic events, symptomatic PE and symptomatic DVT (maximum of 2 trials, 58 women). Adverse effects sufficient to stop treatment were not reported. </p> <p>Subgroup analyses were unable to be conducted due to lack of data, and sensitivity analyses did not impact the main findings. </p> </section> <section id="CD001689-sec-0190"> <h3 class="title" id="CD001689-sec-0190">Overall completeness and applicability of evidence</h3> <p>The evidence to assess the effects of thromboprophylaxis during pregnancy and the early postnatal period in women at increased risk of VTE on the risk of venous thromboembolic disease and adverse effects is very incomplete. While maternal deaths were largely not reported (only three trials reported this outcome and observed no deaths), we cannot assume that none occurred. Due to differences in the interventions assessed by the trials, and/or difference in the types of included participants and their risk factors (when reported), we were able to combine only a few trials limiting ability to detect differences between interventions. Between one and five trials were included in the 13 review comparisons, with eight of these comparisons including single trials. In general the sample sizes of the trials were small. The three largest trials recruited 646 women (<a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a>), 580 women (<a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a>), and 292 women (<a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>). Sample sizes of this order are generally inadequate to detect differences in the incidences of rare outcomes such as thromboembolic events, or death from such events, particularly when two active treatments are compared. </p> <p>The important secondary review outcome 'adverse effects sufficient to stop treatment' was only reported by five trials included within four comparisons. There was a paucity of data reported by the included trials for all other secondary outcomes (e.g. asymptomatic thromboembolic events were reported by only four trials across three comparisons). Unclear and different definitions used in the measurement of some of the secondary outcomes (e.g. bleeding episodes; adverse effects not sufficient to stop treatment) made comparing effects of trials difficult, and prevented synthesising individual effect measures in analyses. It is likely that trial authors had differing definitions of ‘serious”. </p> <p>While the trials conducted to date (and included in this review), have assessed a large number of thromboprophylaxis comparisons, and this update included interventions not identified in the previous version of the review (<a href="./references#CD001689-bbs2-0117" title="BainE , WilsonA , TooherR , GatesS , DavisLJ , MiddletonP . Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD001689. [DOI: 10.1002/14651858.CD001689.pub3]">Bain 2014</a>), gaps remain. The full range of commonly‐used interventions has not been assessed. For example, none of the included trials assessed intermittent pneumatic compression, early mobilisation or surveillance. Some of the older trials assessed thromboprophylaxis methods which are no longer used (such as hydroxyethyl starch (HES) (<a href="./references#CD001689-bbs2-0108" title="PaullJ . A prospective study of dextran-induced anaphylactoid reactions in 5745 patients. Anaesthesia and Intensive Care1987;15:163-7.">Paull 1987</a>)), or are not used as frequently in current thromboprophylactic practice (such as the use of UFH rather than LMWH). </p> <p>The focus of this review was on determining effects of different methods to prevent VTE in pregnancy and the early postpartum period, in women at increased risk of VTE due to a variety of risk factors; further evidence on the use of heparin and other thromboprophylactic drugs on the prevention of miscarriage and other pregnancy outcomes in specific groups of women at high risk of adverse pregnancy outcomes are examined in related Cochrane Reviews (see <a href="./references#CD001689-bbs2-0087" title="deJongPG , KaandorpS , Di NisioM , GoddijnM , MiddeldorpS . Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD004734. [DOI: 10.1002/14651858.CD004734]">de Jong 2014</a>; <a href="./references#CD001689-bbs2-0089" title="DoddJM , McLeodA , WindrimRC , KingdomJ . Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD006780. [DOI: 10.1002/14651858.CD006780]">Dodd 2013</a>; <a href="./references#CD001689-bbs2-0095" title="HamulyákEN , ScheresLJ , MarijnenMC , GoddijnM , MiddeldorpS . Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD012852. [DOI: 10.1002/14651858.CD012852]">Hamulyák 2020</a>). </p> </section> <section id="CD001689-sec-0191"> <h3 class="title" id="CD001689-sec-0191">Quality of the evidence</h3> <p>Overall, study‐level risk of bias was moderate to high (<a href="#CD001689-fig-0002">Figure 2</a>; <a href="#CD001689-fig-0003">Figure 3</a>); while attrition bias was considered mostly low risk, there was high or unclear risk of reporting bias in over 80% of trials (due mostly to the absence of protocols and trials published as abstracts only), and over half of the trials were judged at unclear or high risk of selection bias. Most of the included studies had difficulties with adequate blinding of women and personnel due to the interventions they assessed, and in the majority of the trials it was unclear whether outcome assessors were blinded (though absence of blinding for these objective outcomes did not impact our ratings of the certainty of the evidence). The few potential differences in particular secondary outcomes reported in this review were largely derived from small trials which were not considered to be of high methodological quality; there is a strong possibility that they may be caused by bias or chance. </p> <p>The certainty of evidence (assessed using the GRADE approach) assigned to all critical outcomes reported in 'Summary of findings' tables (<a href="./full#CD001689-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD001689-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001689-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001689-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001689-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001689-tbl-0006">summary of findings Table 6</a>) was very low certainty. Reasons for downgrading included design limitations and considerable imprecision (usually due to low event rates and small numbers of trials per outcome). Although, in a few instances, evidence was also downgraded for indirectness (concerns about applicability of results included vague definition of outcomes (e.g. lack of clarity about whether thromboembolic events were symptomatic), poorly defined VTE risk factors of women in the included trials, and specificity and variation in VTE risk factors of women in the included trials). </p> </section> <section id="CD001689-sec-0192"> <h3 class="title" id="CD001689-sec-0192">Potential biases in the review process</h3> <p>The evidence for this review has been derived from trials identified through a detailed search process. It is possible (but unlikely) that additional trials assessing prophylaxis for VTE in pregnancy have been published but not identified. It is also possible that other trials have been conducted but not published. Should such trials be identified we will include them in future updates of this review. </p> <p>We attempted to reduce bias wherever possible by having at least two review authors independently working on trial selection, data extraction, quality and evidence‐certainty assessments. </p> </section> <section id="CD001689-sec-0193"> <h3 class="title" id="CD001689-sec-0193">Agreements and disagreements with other studies or reviews</h3> <p>A narrative review (<a href="./references#CD001689-bbs2-0079" title="AndrewL , Ni AinleF , BlondonM , RodgerM , SkeithL . Preventing postpartum venous thromboembolism: a call to action to reduce undue maternal morbidity and mortality. Thrombosis Research2020;193:190-7.">Andrew 2020</a>) has described the latest evidence on postpartum VTE prevention in women with modest risk factors, such as those with mild thrombophilias, and transient situational risk factors around labour and birth, including caesareans. Congruent with our review, the authors highlight uncertainty surrounding the effects of postpartum thromboprophylaxis in this group of women, and call for the collection of robust prospective data on VTE risk factors and effects of postpartum thromboprophylaxis. </p> <p>Three related Cochrane Reviews have assessed the effects of the use of thromboprophylaxis (including heparin) in pregnant women. The <a href="./references#CD001689-bbs2-0087" title="deJongPG , KaandorpS , Di NisioM , GoddijnM , MiddeldorpS . Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD004734. [DOI: 10.1002/14651858.CD004734]">de Jong 2014</a> review (conducted prior to the inclusion of GRADE certainty assessments), assessed effects of anticoagulant agents (including aspirin and heparin) in women with a history of at least two unexplained miscarriages, with or without inherited thrombophilia (primary outcome live birth). Consistent with our review, no clear beneficial effects of anticoagulants in trials considered at low risk of bias were found ‐ in the review's comparison of LMWH versus no treatment, no differences between groups were found in individual trials for pregnancy complications, bleeding or thromboembolic events. </p> <p>The <a href="./references#CD001689-bbs2-0095" title="HamulyákEN , ScheresLJ , MarijnenMC , GoddijnM , MiddeldorpS . Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD012852. [DOI: 10.1002/14651858.CD012852]">Hamulyák 2020</a> review, assessed the effects of aspirin and/or heparin for improving pregnancy outcomes in women with persistent (on two separate occasions) antiphospholipid antibodies, either lupus anticoagulant, anticardiolipin or aβ2‐glycoprotein‐I antibodies or a combination, and recurrent pregnancy loss (two or more, which did not have to be consecutive).The review demonstrated low‐certainty evidence that heparin plus aspirin versus aspirin alone may increase the number of live births and reduce the risk of pregnancy loss. Similar to our review, the authors were very uncertain if heparin (plus aspirin versus aspirin alone) has any effect on adverse effects (bleeding) in the mother; no cases of thrombocytopenia, allergic reactions, venous or arterial thromboembolism or congenital malformations were reported (<a href="./references#CD001689-bbs2-0095" title="HamulyákEN , ScheresLJ , MarijnenMC , GoddijnM , MiddeldorpS . Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD012852. [DOI: 10.1002/14651858.CD012852]">Hamulyák 2020</a>). </p> <p>Trials assessing the effects of antithrombotic therapy for improving maternal or infant health outcomes specifically in women considered at risk of placental dysfunction were included in the <a href="./references#CD001689-bbs2-0089" title="DoddJM , McLeodA , WindrimRC , KingdomJ . Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD006780. [DOI: 10.1002/14651858.CD006780]">Dodd 2013</a> review, which focused on outcomes largely different to those included in this review. While the review (also conducted prior to the inclusion of GRADE certainty assessments), demonstrated potential benefits of the use of heparin versus no treatment ‐ with reductions in perinatal mortality, preterm birth and infant birthweight below the 10th centile for gestational age observed ‐ similar to our review, a lack of reliable information regarding clinically relevant, serious adverse infant health outcomes was identified (<a href="./references#CD001689-bbs2-0089" title="DoddJM , McLeodA , WindrimRC , KingdomJ . Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD006780. [DOI: 10.1002/14651858.CD006780]">Dodd 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001689-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD001689-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001689-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001689-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 4: Blood transfusion" data-id="CD001689-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 4: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 5: Bleeding episodes" data-id="CD001689-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 5: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 6: Serious wound complications" data-id="CD001689-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 6: Serious wound complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 7: Adverse effects sufficient to stop treatment" data-id="CD001689-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 7: Adverse effects sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 8: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 8: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 9: Symptomatic osteoporosis" data-id="CD001689-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 9: Symptomatic osteoporosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 10: Fetal loss" data-id="CD001689-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 10: Fetal loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 11: Thrombocytopenia" data-id="CD001689-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 11: Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 12: Fetal anomalies" data-id="CD001689-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 12: Fetal anomalies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 4: Blood transfusion" data-id="CD001689-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 4: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 5: Bleeding episodes" data-id="CD001689-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 5: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 6: Adverse effects sufficient to stop treatment" data-id="CD001689-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 6: Adverse effects sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 7: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 7: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 8: Symptomatic osteoporosis" data-id="CD001689-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 8: Symptomatic osteoporosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 9: Fetal loss" data-id="CD001689-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 9: Fetal loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 10: Thrombocytopenia" data-id="CD001689-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Antenatal (± postnatal) prophylaxis: LMWH versus UFH, Outcome 10: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 4: Asymptomatic thromboembolic events" data-id="CD001689-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 4: Asymptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 5: Bleeding episodes" data-id="CD001689-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 5: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 6: Adverse effects sufficient to stop treatment" data-id="CD001689-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 6: Adverse effects sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 7: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 7: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 8: Fetal loss" data-id="CD001689-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 8: Fetal loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 9: Thrombocytopenia" data-id="CD001689-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH, Outcome 9: Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antenatal (± postnatal) prophylaxis: Compression stockings versus none, Outcome 1: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Antenatal (± postnatal) prophylaxis: Compression stockings versus none, Outcome 1: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antenatal (± postnatal) prophylaxis: Compression stockings versus none, Outcome 2: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Antenatal (± postnatal) prophylaxis: Compression stockings versus none, Outcome 2: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Peripartum/postnatal prophylaxis: UFH versus no treatment, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Peripartum/postnatal prophylaxis: UFH versus no treatment, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Peripartum/postnatal prophylaxis: UFH versus no treatment, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Peripartum/postnatal prophylaxis: UFH versus no treatment, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Peripartum/postnatal prophylaxis: UFH versus no treatment, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Peripartum/postnatal prophylaxis: UFH versus no treatment, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 1: Maternal death" data-id="CD001689-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 1: Maternal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 2: Symptomatic thromboembolic events" data-id="CD001689-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 2: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 3: Symptomatic pulmonary embolism" data-id="CD001689-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 3: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 4: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 4: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 5: Blood transfusion" data-id="CD001689-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 5: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 6: Bleeding episodes (variously defined)" data-id="CD001689-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 6: Bleeding episodes (variously defined) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 7: Serious wound complications" data-id="CD001689-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 7: Serious wound complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 8: Adverse effects sufficient to stop treatment" data-id="CD001689-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 8: Adverse effects sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 9: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo, Outcome 9: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 1: Asymptomatic thromboembolic events" data-id="CD001689-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 1: Asymptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 2: Blood transfusion" data-id="CD001689-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 2: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 3: Bleeding episodes" data-id="CD001689-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 3: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 4: Serious wound complications" data-id="CD001689-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Peripartum/postnatal prophylaxis (caesarean): HES versus UFH, Outcome 4: Serious wound complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 4: Bleeding episodes" data-id="CD001689-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 4: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 5: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 5: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 6: Thrombocytopenia" data-id="CD001689-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH, Outcome 6: Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 1: Maternal death" data-id="CD001689-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 1: Maternal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 2: Symptomatic thromboembolic events" data-id="CD001689-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 2: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 3: Symptomatic pulmonary embolism" data-id="CD001689-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 3: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 4: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 4: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 5: Bleeding episodes" data-id="CD001689-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 5: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 6: Serious wound complications" data-id="CD001689-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 6: Serious wound complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 7: Thrombocytopenia" data-id="CD001689-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH, Outcome 7: Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 4: Blood transfusion" data-id="CD001689-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 4: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 5: Serious wound complications" data-id="CD001689-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH, Outcome 5: Serious wound complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 4: Bleeding episodes (excessive bruising)" data-id="CD001689-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 4: Bleeding episodes (excessive bruising) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 5: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types), Outcome 5: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 4: Blood transfusion" data-id="CD001689-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest, Outcome 4: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 1: Maternal death" data-id="CD001689-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 1: Maternal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 2: Symptomatic thromboembolic events" data-id="CD001689-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 2: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 3: Symptomatic pulmonary embolism" data-id="CD001689-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 3: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 4: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 4: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 5: Asymptomatic thromboembolic events" data-id="CD001689-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 5: Asymptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 6: Bleeding episodes" data-id="CD001689-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 6: Bleeding episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 7: Adverse effects not sufficient to stop treatment" data-id="CD001689-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 7: Adverse effects not sufficient to stop treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-013.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 8: Thrombocytopenia" data-id="CD001689-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-013.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13: Postnatal prophylaxis: LMWH versus no treatment/placebo, Outcome 8: Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-013.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo, Outcome 1: Symptomatic thromboembolic events" data-id="CD001689-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo, Outcome 1: Symptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo, Outcome 2: Symptomatic pulmonary embolism" data-id="CD001689-fig-0095" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo, Outcome 2: Symptomatic pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001689-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/urn:x-wiley:14651858:media:CD001689:CD001689-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo, Outcome 3: Symptomatic deep vein thrombosis" data-id="CD001689-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_t/tCD001689-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo, Outcome 3: Symptomatic deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/media/CDSR/CD001689/image_n/nCD001689-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001689-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment/placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment/placebo for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> pregnant women at increased risk of VTE during pregnancy and the early postnatal period </p> <p><b>Settings:</b> UK (2 trials), Australia and Sweden (1 trial), Canada and USA (1 trial), Australia, the Netherlands and Sweden (1 trial) </p> <p><b>Intervention:</b> heparin (LMWH (4 trials) or UFH (1 trial)) </p> <p><b>Comparison:</b> no treatment (3 trials) or placebo (2 trials) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no treatment/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(follow‐up: 6 weeks postpartum</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.39 (0.08 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>476</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 trial reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000 (1 to 34)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33 (0.02 to 7.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 trials reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 77) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33 (0.04 to 3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 trials reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 (1 to 55)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.49 (0.05 to 5.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>139</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 3, 4</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 events: heparin (LMWH) 1 event (bleeding from placental praevia); no treatment 2 events (both stomach complaints) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(1 to 154) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>LMWH</b> : low molecular weight heparin; <b>PE:</b> pulmonary embolism; <b>RR:</b> Risk Ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of selective reporting bias; not downgraded for lack of blinding as unlikely to have influenced objective outcome </p> <p><sup>2</sup> Imprecision (‐2): few events and wide confidence intervals crossing the line of no effect </p> <p><sup>3</sup> Indirectness (‐1): women had specific risk factors for VTE during pregnancy and the postpartum period which varied across the trials, and risk factors also varied across women within the trials, limiting applicability of results to all pregnant women and women in the early postnatal period at increased risk of VTE </p> <p><sup>4</sup> Imprecision (‐2): few events and small sample size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001689-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: LMWH versus UFH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antenatal (± postnatal)</b> <b>prophylaxis: LMWH versus UFH for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> pregnant women at increased risk of VTE during pregnancy and the early postnatal period </p> <p><b>Settings:</b> Finland (1 trial), USA (3 trials) </p> <p><b>Intervention:</b> LMWH </p> <p><b>Comparison:</b> UFH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(Follow‐up: during or immediately following delivery or 6‐8 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.47 (0.09 to 2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>404</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 trials reported no events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(2 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(Follow‐up: during or immediately following delivery or 6‐8 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>287<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><sup>⊕⊝⊝⊝</sup> </p> <p>very low <sup>1, 4, 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(Follow‐up: during or immediately following delivery or 6‐8 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>287</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><sup>⊕⊝⊝⊝</sup> </p> <p>very low <sup>1, 4, 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.07 (0.01 to 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>226</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1,</sup><sup>6, 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13 events in UFH group: 1 stopped due to an allergic reaction, 1 due to mild anaemia with no confirmed bleeding and 11 due to excess bruising/allergic rashes (these 11 stopped switched to LMWH (dalteparin) and the adverse effects resolved) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(1 to 61) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT</b> : deep vein thrombosis; <b>LMWH</b> : low molecular weight heparin; <b>NA</b> : not applicable; <b>PE:</b> pulmonary embolism; <b>RR:</b> Risk Ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of selection, attrition and selective reporting bias; not downgraded for lack of blinding as inadequate blinding unlikely to have influenced objective outcome </p> <p><sup>2</sup> Imprecision (‐2): few events and wide confidence interval crossing line of no effect </p> <p><sup>3</sup> Indirectness (‐1): not clear if the events were symptomatic, described as "recurrent thrombosis"; further women had specific risk factors, limiting applicability of results to all pregnant women and women in the early postnatal period at increased risk of VTE </p> <p><sup>4</sup> Imprecision (‐2): no events and small sample size </p> <p><sup>5</sup> Indirectness (‐1): women had specific risk factors, limiting applicability of results to all pregnant women and women in the early postnatal period at increased risk of VTE </p> <p><sup>6</sup> Few events and small sample size </p> <p><sup>7</sup> Indirectness (‐1): risk factors for VTE poorly described in 1 of the trials (with most weight in the meta‐analysis) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: LMWH versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001689-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Peripartum/postnatal prophylaxis: UFH versus no treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peripartum/postnatal prophylaxis: UFH versus no treatment for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth </p> <p><b>Settings:</b> Israel (1 RCT) </p> <p><b>Intervention:</b> UFH </p> <p><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no UFH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16 (0.02 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(1 to 72)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16 (0.01 to 3.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 71)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(follow‐up: 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27 (0.03 to 2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(1 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk Ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of all sources of bias other than attrition (low risk); not downgraded for lack of blinding as objective outcome </p> <p><sup>2</sup> Imprecision (‐2): wide confidence intervals crossing line of no effect, few events, and small sample size </p> <p><sup>3</sup> Indirectness (‐1): specific risk factors for VTE of included women limits applicability of findings to all women at increased risk of VTE intrapartum and in the early postnatal period </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Peripartum/postnatal prophylaxis: UFH versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001689-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment/placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment/placebo for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials)) </p> <p><b>Settings:</b> Australia (1 trial), Saudi Arabia (1 trial), Switzerland (1 trial), UK (2 trials) </p> <p><b>Intervention:</b> heparin <b>(</b>LMWH (3 RCTs), UFH (2 RCTs)) </p> <p><b>Comparison</b>: no treatment (1 trial) or placebo (4 trials) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no heparin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal death</p> <p>(timing of assessment unclear)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA<br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> 300</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> ⊕⊝⊝⊝</p> <p>very low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events<br/> <br/> <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30 (0.39 to 4.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>840</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(4 to 29)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10 (0.25, 4.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>840<br/>(4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(2 to 33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.30 (0.24, 6.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1140<br/>(5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3, 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(1 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>2, 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>NA</b> : not applicable; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk Ratio; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐2) one trial at unclear risk of all sources of bias </p> <p><sup>2</sup> Imprecision (‐2): no events and small sample size </p> <p><sup>3</sup> Design limitations (‐2): most trials at unclear risk of selection bias, all trials at unclear risk of selective reporting; not downgraded for lack of blinding as objective outcome </p> <p><sup>4</sup> Imprecision (‐1): wide confidence intervals crossing line of no effect </p> <p><sup>5</sup> Design limitations (‐1): unclear risk of selective reporting bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001689-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial), elective/emergency unclear (1 trial)) </p> <p><b>Settings:</b> German (2 trials); UK (1 trial) </p> <p><b>Intervention:</b> LMWH </p> <p><b>Comparison:</b> UFH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33 (0.01 to 7.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>217<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All the events were symptomatic DVT</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>2 to 75) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>217<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>1, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Symptomatic DVT</p> <p>(timing of assessment unclear, within 6 weeks postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33 (0.01 to 7.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>217<br/>(3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000<br/>2 to 75) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>LMWH</b> : low molecular weight heparin; <b>NA</b> : not applicable; PE: pulmonary embolism; <b>RR:</b> Risk Ratio; <b>UFH</b>: unfractionated heparin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐2): all trials at unclear risk of selection bias, selective reporting and other bias; not downgraded for lack of blinding as objective outcome </p> <p><sup>2</sup> Imprecision (‐2): wide confidence intervals crossing line of no effect, few events and small sample size </p> <p><sup>3</sup> Imprecision (‐2): no events and small sample size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001689-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Postnatal prophylaxis: LMWH versus no treatment/placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Postnatal prophylaxis: LMWH versus no treatment/placebo</b> <b>for venous thromboembolic disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women at increased risk of VTE in the early postpartum period </p> <p><b>Settings:</b> multi‐country, Canada and USA (2 trials) </p> <p><b>Intervention:</b> LMWH </p> <p><b>Comparison:</b> no treatment (1 trial) or placebo (1 trial) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with no heparin treatment or placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal death</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> <p>Maternal death only reported as: “no… other unexpected serious adverse events related to the intervention during follow‐up” </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic thromboembolic events</p> <p>(follow‐up: 10‐90 days postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58<br/>(2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE</p> <p>(follow‐up: 10‐90 days postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58<br/>(2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT</p> <p>(follow‐up: 10‐90 days postpartum)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>58</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects sufficient to stop treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>DVT:</b> deep vein thrombosis; <b>NA</b> : not applicable; <b>PE:</b> pulmonary embolism; <b>RR:</b> Risk Ratio; <b>VTE</b>: venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Design limitations (‐1): unclear risk of selective reporting and other bias </p> <p><sup>2</sup> Imprecision (‐2): no events and small sample size </p> <p><sup>3</sup> Design limitations (‐1): unclear risk of selective reporting and other bias; not downgraded for lack of blinding as objective outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Postnatal prophylaxis: LMWH versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001689-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions and studies in each comparison</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i><b>Antenatal (± postnatal)</b> </i><b>prophylaxis</b> (n = 11 RCTs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 1</b> ‐ Heparin (LMWH or UFH) versus no treatment or placebo </p> <p><a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a>; <a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a>; <a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a>; <a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a>; <a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 2</b> ‐ LMWH versus UFH </p> <p><a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a>; <a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a>; <a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a>; <a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 3</b> ‐ Adjusted‐ versus fixed‐dose LMWH </p> <p><a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 4</b> ‐ Compression stockings versus none </p> <p><a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i><b>Peripartum/postnatal</b> </i><b>prophylaxis</b> (n = 14 RCTs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaginal birth or caesarean</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 5</b> ‐ UFH versus no heparin treatment </p> <p><a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Caesarean</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 6</b> ‐ Heparin (LMWH or UFH) versus no treatment or placebo </p> <p><a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a>; <a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a>; <a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a>; <a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a>; <a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 7</b> ‐ HES versus UFH </p> <p><a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 8</b> ‐ LMWH versus UFH </p> <p><a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a>*; <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a>*; <a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 9</b> ‐ 5‐day versus 10‐day LMWH </p> <p><a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 10</b> ‐ Weight‐based versus fixed‐dose LMWH </p> <p><a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 11</b> ‐ LMWH versus LMWH (different types) </p> <p><a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a>* </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison 12</b> ‐ Compression devices versus bed rest </p> <p><a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Postnatal prophylaxis</b> (n = 2 RCTs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison 13 ‐ LMWH versus no treatment or placebo</p> <p><a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a>; <a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p>*Trial had three arms. <a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a> assessed three different types of heparin, and we included all three groups in the review analysis as pair‐wise comparisons; <a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a> included two separate LMWH groups and an UFH group, and for this trial we combined the two LMWH groups in the review meta‐analysis. <a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a> included two randomised treatment groups, and a non‐randomised control (no treatment group), so for this trial we included only the two treatment groups. </p> <p>Two additional studies are included in the review (<a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>; <a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>), both of which assessed intrapartum (+ postnatal) prophylaxis (pharmacologic), although are not included in the review comparisons as they contributed no outcomes for analysis. </p> <p>Abbreviations: <b>RCT</b> : randomised controlled trial; <b>LMWH</b> : low molecular weight heparin; <b>UF</b>: unfractionated heparin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions and studies in each comparison</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001689-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Personal history of VTE</b> </p> <p><b>(all/none/mixed NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Known acquired or inherited thrombophilia</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Obesity (BMI ≥ 30 kg/m<sup>2</sup>)</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Advanced age (e.g. ≥ 35 years)</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pre‐eclampsia</b> </p> <p><b>(all/none/mixed/NR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>If post caesarean prophylaxis (emergency/elective/mixed/NR)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0001" title="AlgahtaniF , AL DohamiH , Abo-HarbeshS , GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2012;130(Suppl 1):S197. AlgahtaniF , GaderA , AleemA , Al DohamiH , GarbeshS . Thromboembolism prophylaxis after cesarean section (pro-cs) trial. Haematologica2013;98:749-50. AlgahtaniFH , Al-DohamiH , Abo-HarbeshS , Al-GaderA , AleemA . Thromboembolism prophylaxis after cesarean section (PRO-CS) trial. Thrombosis Research2015;135(Suppl 1):S71. NCT01321788. Venous Thromboembolism Prophylaxis Post Cesarean Section (PROCS). https://clinicaltrials.gov/ct2/show/NCT01321788 (first received 24 March 2011). ">Algahtani 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0002" title="BurrowsRF , GanET , GallusAS , WallaceEM , BurrowsEA . A randomised, double blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology2001;108:835-9. ">Burrows 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (though "Need of therapy with an anticoagulant" was listed as an exclusion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0003" title="CaseleH , HaneyE , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women receiving thromboprophylaxis in pregnancy [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S14. CaseleH , HaneyEI , JamesA , Rosene-MontellaK , CarsonM . Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology2006;195:1109-13. CaseleH . Thrombosis prophylaxis in pregnancy. www.enh.org (accessed 14 June 2005). ">Casele 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (only reports that "Any patient who was a candidate for low‐dose thromboprophylaxis" were included) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0004" title="CornetteJ , JacquemynY , VercauterenM , BuytaertP . A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology2002;17:67-9. ">Cornette 2002</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (women with known coagulation or bleeding disorders were excluded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (based on discussion, and apparent exclusion of women with pre‐eclampsia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0005" title="CruzM , Fernández-AlonsoA , GarrigosaL , CanoA , CarreteroP , VizcainoA , et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin [Article ID 548327]. Obstetrics and Gynecology International 2011 Dec 26 [Epub ahead of print]. ">Cruz 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (only reports that "women... who had not required prophylaxis or treatment with any type of LMWH during pregnancy (low risk of VTE during pregnancy)" were included) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (based on baseline characteristics reported ‐ only reported pregnancy‐induced hypertension) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0006" title="De VecianaM , TrailP , DattelB , SlotnickRN , AbuhamadA . Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy [abstract]. American Journal of Obstetrics and Gynecology2001;185(6):S182. ">De Veciana 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0007" title="AbheidenC , Van HoornME , HagueWM , KostensePJ , vanPampusMG , deVriesJ . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an international journal of obstetrics and gynaecology2016;123(5):797-805. ISRCTN87325378. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). http://www.isrctn.com/ISRCTN87325378 (first received 1 November 2005). NTR337. Low molecular weight heparin (Fragmin (R)) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (FRUIT-study). Https://www.trialregister.nl/trial/299 (first received 2005). deVriesJ , vanPampusMG , HagueWM , BezemerPD , JoostenJH . Fractionated heparin in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences2011;18(3 Suppl 1):69A. deVriesJI , HagueWM , Van PampusMG , for the FRUIT-RCT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. Journal of Thrombosis &amp; Haemostasis2012;10(6):1196. deVriesJI , vanPampusMG , HagueWM , BezemerPD , Joosten JH and on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis2012;10:64-72. ">de Vries 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0008" title="EllisonJ , ThomsonAJ , ConkieJA , McCallF , WalkerID , GreerIA . Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis2001;86:1374-8. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Comparisons of the anti-factor XA activities of three commonly used low molecular weight heparins following caesarean section. Scottish Medical Journal2000;45(3):94-5. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of dalteparin, enoxaparin and tinzaparin. British Journal of Obstetrics and Gynaecology2000;107:823. EllisonJ , ThomsonAJ , WalkerID , GreerIA . Thromboprophylaxis following caesarean section: comparison of the anti-factor Xa activities of three commonly used low molecular weight heparins. Journal of Obstetrics and Gynaecology2000;20(Suppl 1):S39-S40. ">Ellison 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0009" title="BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. GatesS , BrocklehurstP , DavisLJ . Antenatal thromboprophylaxis using low molecular weight heparin (enoxaparin) for women at risk of thromboembolic disease: multicentre placebo controlled randomised trial (APPLE) and systematic review. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S44. National Perinatal Epidemiology Unit. The APPLE Study. www.npeu.ox.ac.uk/trials/apple.html (first received 12 January 2001). ">Gates 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/mixed (only reports booking weight ≥ 80 kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0010" title="BrocklehurstP , GatesS . Randomised controlled trial (PEACH) and meta-analysis of thromboprophylaxis using low-molecular weight heparin (enoxaparin) after caesarean section. Journal of Obstetrics and Gynaecology2002;22(2 Suppl):S52. BrocklehurstP , Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis in pregnancy trials: apple, plum and peach. British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):53. GatesS , BrocklehurstP , AyersS , BowlerU . Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. American Journal of Obstetrics and Gynecology2004;191:1296-303. National Perinatal Epidemiology Unit. The PEACH Study. www.npeu.ox.ac.uk/trials/peach.html (first received 12 January 2001). ">Gates 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/mixed (only reports booking weight ≥ 80 kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0011" title="GibsonJL , EkevallK , WalkerI , GreerIA . Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology1998;105:795-7. ">Gibson 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (women "undergoing caesarean section were recruited to the study if this procedure was performed as an emergency... or if they had 1 or more of the other defined risk factors for thromboembolic disease"; "Additional risk factors include advanced maternal age, high parity, obesity, pre‐eclampsia and prolonged bed rest before delivery"; however, no baseline characteristics detailed). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (see left)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0012" title="HamersleyS , LandyH . Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin [abstract]. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S66. ">Hamersley 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0013" title="HeilmanL , HeitzR , KochFU , OseC . Perioperative thrombosis prophylaxis at the time of caesarean section: results of a randomised prospective comparative study with 6% hydroxyethyl starch 0.62 and low dose heparin [Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyathylstarke 0,62 und Low-dose-Heparin]. Zeitschrift fur Geburtshilfe und Perinatologie1991;195:10-5. ">Heilmann 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (1 woman in HES group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0014" title="HeilmannL , RathW , PollowK , BickRL . The rheological changes after cesarean section: the influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clinical Hemorheology and Microcirculation2007;37:211-8. ">Heilmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/mixed/none (1 woman in LMWH group had BMI &gt; 26 kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0015" title="HellerJ , CannerJ , Wei LumY , TsuchiyaK . Compression stockings during pregnancy: essential or superfluous? A pilot study. Journal of Vascular Surgery: Venous and Lymphatic Disorders2016;4(1):148. NCT01793194. Preventing the development of venous insufficiency in pregnant women through use of compression stockings: a randomized pilot study. http://www.clinicaltrials.gov/ct2/show/NCT01793194 (first received 21 May 2013). ">Heller 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0016" title="HillNC , HillJG , SargentJM , TaylorCG , BushPV . Effect of low dose heparin on blood loss at caesarean section. BMJ1988;296:505-6. HillNC , HillJG , SargentJM , TaylorCG , BushPV . The effect of low dose heparin on blood loss at caesarean section. In: 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988. ">Hill 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (women with coagulation disorders were excluded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/none (women with pregnancy‐induced hypertension were excluded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0017" title="HowellR , FidlerJ , LetskyE , deSwietM . The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology1983;90:1124-8. ">Howell 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0018" title="KraussT , RathW , DittmerU , KuhnW . Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics [Thromboembolieprophylaxe mit niedermolekularen Heparin (Fragmin)in der Geburtshilfe]. Zeitschrift fur Geburtshilfe und Perinatologie1994;198:120-5. ">Krauss 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0019" title="O'RiordanMN , HorganR , AryaA , QuinnS , GaolebalePA , SarkarRK , et al. Pharmokinetics of low molecular weight heparins in the postpartum period. In: Irish Perinatal Society Annual Meetings; 2008 April 11-12; Cork, Ireland. 2008:10. ">O'Riordan 2008</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0020" title="PettilaV , KaajaR , LeinonenP , EkbladU , KatajaM , IkkalaE . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research1999;96:275-82. PettilaV , LeinonenP , MarkkolaA , HiilesmaaV , KaajaR . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis2002;87(2):182-6. ">Pettila 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/none? (reported as an outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0021" title="ReddickKL , SmrtkaMP , GrotegutCA , JamesAH , BrancazioLR , SwamyGK . The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. American Journal of Perinatology2014;31(9):735-40. ">Reddick 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elective</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0022" title="Abou-NassarK , KovacsMJ , KahnSR , WellsP , DoucetteS , RamsayT , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis2007;98(1):163-71. Abou-NassarK , RodgerM , KovacsMJ , DoucetteS , TimR , KahnS , et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood2006;108(11 Pt 1):262. NCT00967382. Thrombophilia in pregnancy prophylaxis study (TIPPS). http://www.clinicaltrials.gov/ct2/show/NCT00967382 (first received 30 January 2013). RodgerM , HagueWM , KingdomJ , KahnSR , KarovitchA , WellsPS , et al. The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): a multi-national randomized trial of dalteparin vs. no dalteparin to prevent pregnancy complications in pregnant thrombophilic women. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):78. RodgerMA , HagueWM , KingdomJ , KahnSR , KarovitchA , SermerM , et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet2014;384:1673-83. RodgerMA , KahnS , CranneyA , HodsonA , KovacsM , ClementAM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy2006;25(Suppl 1):8. RodgerMA , KahnSR , CranneyA , HodsmanA , KovacsMJ , ClementAM , et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis2007;5:1600-6. RodgerMA , Lazo-LangnerA , KahnS , KovacsM , RobinsonS , BlosteinM , et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood2005;106(11):Abstract No 548. RodgersM . Thrombophilia in pregnancy prophylaxis study (TIPPS). Ottawa Health Research Institute (http://www.ohri.ca) (accessed 17 July 2002). ">Rodger 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR/none? (reported as an outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0023" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , JamesAH , KonkleBA . Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis2015;113(1):212-6. ">Rodger 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (vaginal births also included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0024" title="NCT01274637. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. http://clinicaltrials.gov/show/NCT01274637 (first received 15 February 2011). RodgerMA , PhillipsP , KahnSR , BatesS , McDonaldS , KhuranaR , et al. Low molecular weight heparin to prevent postpartum venous thromboembolism. A pilot study to assess the feasibility of a randomized open-label trial. Thrombosis Research2016;142:17-20. ">Rodger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0025" title="GarmiG , OkopnikM , Zuarez-EastonS , ZafranN , RomanoS , SalimR . Placental findings following adjusting enoxaparin dosage according to anti-fxa levels in thrombophilic women. A randomized controlled trial. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S457. GarmiG , ZafranN , OkopnikM , GavishI , RomanoS , SalimR . Placental pathological findings following adjusting enoxaparin dosage in thrombophilic women: secondary analysis of a randomized controlled trial. Thrombosis and Haemostasis2019;119(1):87-91. NCT01068795. Dose adjusting enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels improve pregnancy outcome. http://clinicaltrials.gov/show/NCT01068795 (first received 18 June 2013). SalimR , NachumZ , GavishI , RomanoS , BravermanM , GarmiG . Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. Thrombosis and Haemostasis2016;116(4):687-95. ">Salim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0026" title="SegalS , SadovskyE , WeinsteinD , PolishukWZ . Prevention of postpartum venous thrombosis with low doses of heparin. European Journal of Obstetrics and Gynecology and Reproductive Biology1975;5:273-6. ">Segal 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed (vaginal births also included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0027" title="NCT02070237. Comparing anti-XA levels in post-cesarean patients undergoing enoxaparin thromboprophylaxis. https://clinicaltrials.gov/ct2/show/NCT02070237 (first received 25 February 2014). StephensonM , SerraA , NeeperJ , CaballeroD , McNultyJ . Comparing anti-Xa levels in women with body mass index &gt;/=35 post cesarean delivery undergoing enoxaparin thromboprophylaxis with weight-based dosing twice daily versus fixed dose 40 mg daily: a randomized, controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S18. StephensonML , SerraAE , NeeperJM , CaballeroDC , McNultyJ . A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology2016;36(2):95-9. ">Stephenson 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0028" title="vanHoornM , HagueWM , vanPampusM , BezemerD , de Vries J for the FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;197:168-73. ">van Hoorn 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001689-bbs2-0029" title="WeltiH . Prevention of thromboembolism by physiotherapy with and without low dose heparin in gynecology and obstetrics. Results of a controlled, randomized multicenter study [Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologie-obstetrique]. Revue Medicale de la Suisse Romande1981;101(11):925-34. ">Welti 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Abbreviations: <b>BMI</b> : body mass index;<b>HES</b> : hydroxyethyl starch; <b>LMWH:</b> low molecular weight heparin; <b>NR</b> : not reported; <b>NA</b> : not applicable; <b>VTE</b>: venous thromboembolism </p> <p>*No outcomes included in the review analyses.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/full#CD001689-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 LMWH: placental abruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.31, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 LMWH: peripartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 LMWH non‐major/minor bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.15, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 LMWH: major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.25, 8.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 UFH: antenatal vaginal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.16, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 UFH: postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Serious wound complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse effects sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 LMWH: skin/allergic reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.11 [2.00, 13.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 LMWH: raised liver enzymes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.53 [1.34, 378.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 LMWH: haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.98 [0.46, 34.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Superficial thrombophlebitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 LMWH: other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Symptomatic osteoporosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Fetal loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 LMWH or UFH: gestation unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.54, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 LMWH: &lt; 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.50, 9.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 LMWH: ≥ 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 64.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 64.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Fetal anomalies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.60, 14.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: Heparin (LMWH or UFH) versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: LMWH versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.09, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Bruises &gt; 1 inch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.09, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Bleeding at birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [0.44, 32.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Bleeding complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse effects sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Injection burning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.53, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Symptomatic osteoporosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.06, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Fetal loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Gestation unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.21, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 &lt; 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: LMWH versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Asymptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Placental abruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Side effects: bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Adverse effects sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Skin allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Fetal loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 &lt; 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [0.22, 91.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 ≥ 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.11, 64.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antenatal (±postnatal) prophylaxis: Adjusted‐dose versus fixed‐dose LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: Compression stockings versus none</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antenatal (± postnatal) prophylaxis: Compression stockings versus none</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Peripartum/postnatal prophylaxis: UFH versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Peripartum/postnatal prophylaxis: UFH versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.39, 4.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [0.31, 28.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.19, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.25, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.13, 74.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.13, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.24, 6.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.17, 11.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.07, 18.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Bleeding episodes (variously defined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 Major bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.3 Bleeding complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.03 [2.49, 10.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.4 Bleeding/bruising reported at discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.17 [0.76, 49.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.5 Blood loss &lt; 500 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.63, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.6 Blood loss 500‐1000 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.50, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.7 Blood loss 1000‐1500 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.8 Blood loss 1500‐2000 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 20.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Serious wound complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 Major wound disruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 Wound infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.34, 15.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Adverse effects sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): Heparin (LMWH or UFH) versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): HES versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Asymptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.27, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Serious wound complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.25, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): HES versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 "haemorrhagic event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.3 Post surgical haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.01, 8.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.01, 8.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Serious wound complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.1 Post caesarean infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.63, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.2 Post caesarean seroma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.59, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): 5‐day versus 10‐day LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Serious wound complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Wound dehiscence or reoperation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 Wound infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.3 Wound haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): Weight‐based versus fixed‐dose LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Dalteparin versus enoxaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Dalteparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 Enoxaparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Dalteparin versus enoxaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 Dalteparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.3 Enoxaparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 Dalteparin versus enoxaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 Dalteparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.3 Enoxaparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Bleeding episodes (excessive bruising) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 Dalteparin versus enoxaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.2 Dalteparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.3 Enoxaparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 Dalteparin versus enoxaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.2 Dalteparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.3 Enoxaparin versus tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Peripartum/postnatal prophylaxis (caesarean): Compression devices versus bed rest</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Postnatal prophylaxis: LMWH versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Asymptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.6 Bleeding episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.1 Major bleeding event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.15, 81.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.2 Clinically relevant bleeding event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.88 [0.30, 114.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.3 Minor bleeding event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.15, 81.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.7 Adverse effects not sufficient to stop treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.15, 81.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.8 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Postnatal prophylaxis: LMWH versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Sensitivity analysis: antenatal (± postnatal) prophylaxis with LMWH versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001689-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Symptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.13, 74.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.13, 74.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Symptomatic deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Sensitivity analysis: peripartum/postnatal prophylaxis (caesarean) with LMWH versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001689.pub4/references#CD001689-tbl-0024">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001689.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001689-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001689-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001689-note-0024">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001689-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001689-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001689-note-0023">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD001689-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD001689-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001689-note-0025">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD001689-note-0014">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001689-note-0022">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001689-note-0020">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001689-note-0021">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001689\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001689\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001689\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001689\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001689\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001689.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001689.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001689.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001689.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001689.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714821285"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001689.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714821289"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001689.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7805fd07937d',t:'MTc0MDcxNDgyMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 